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Abstract
This study assessed the effectiveness of specific elements of an innovative
colonoscopy clinical protocol, namely use of a hands-on 2-person technique (vs. solo
performance) and use of propofol sedation in enhancing the performance quality of
screening colonoscopies by trained primary care physicians (PCP) and specialists. The
study used data from a state-licensed ambulatory surgery center for endoscopy in South
Carolina from September 4, 2001 to February 4, 2011. This center has trained 54 PCPs in
colonoscopy performance since 2001. Post training, PCPs are credentialed to perform
colonoscopy only with the 2-person technique with a specialist available onsite to provide
rescue assistance. A total of 59 physicians performed colonoscopies, and 57 physicians
(54 PCPs and 3 specialists) consistently complied with the 2-person technique, while 2
non PCPs (one colorectal surgeon and one general surgeon) used the conventional solo
performance technique. Propofol sedation in lieu of the conventionally used midazolammeperidine (MM) sedation was implemented since April 1, 2006.
The dependent variables of interest representing procedure quality were as
follows: procedure time, the likelihood of finding a/an polyp/adenoma/advanced
neoplasm, finding an additional polyp/adenoma, finding at least one right-sided polyp,
and finding increasingly smaller polyps. These quality indicators were found to be
positively associated with the 2-person technique protocol. There was a marginal gain on
some of the measures with the use of propofol sedation. The findings suggest that the 2person technique as implemented by this center improves the global quality of
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colonoscopy performance on measures that are documented to predict colorectal cancer
prevention effectiveness.
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Chapter 1

RESEARCH BACKGROUND AND SIGNIFICANCE

This chapter describes the background and the significance of the study topic.
1.1 Study Background
Colorectal cancer (CRC) is the third most prevalent cancer and second leading
cause of cancer death in the U.S. (U.S. Cancer Statistics Working Group), with
almost140, 000 new cases and 55,000 deaths annually. This large number affected can be
mostly prevented by screening tests both by removing pre-cancerous lesions and by early
detection. In the past decade, age-adjusted CRC incidence decreased from 51.8 per
100,000 in 1999 to 44.7 per 100,000 in 2009; as well as age-adjusted CRC mortality,
which decreased from 20.5 per 100,000 to 16.9 per 100,000 (SEER 1990-2010).
Despite some degree of annual reductions in CRC incidence and mortality, CRC
remains a major threat to public health when compared to the motor vehicle accident
fatality rate of about 11 per 100,000 annually (NHTSA 2012). Evidence indicates that
screening tests, such as fecal occult blood test (FOBT) and fecal immunochemical test
(FIT), sigmoidoscopy, and colonoscopy etc, availed at appropriate intervals, can reduce
the risk of CRC to some extent by enabling the early detection and removal of advanced
polyps. The American Cancer Society in 1992 and the U.S. Preventive Services Task
Force (USPSTF) in 1996 initiated the earliest guidelines recommending CRC screening
of average risk individuals, who are aged 50 years and older to undergo routine
1

screenings until the age of 75. Currently, the USPSTF recommended screening
tests and intervals are:
•

Annual screening with high-sensitivity fecal occult blood testing

•

Sigmoidoscopy every 5 years, with high-sensitivity fecal occult blood testing

every 3 years
•

Colonoscopy every 10 years
Colonoscopies have been recommended as the preferred screening method,

including the American College of Obstetricians and Gynecologists, the American
College of Gastroenterology (Rex 2000, Rex 2009) and the American Society for
Gastrointestinal Endoscopy (ASGE) (David 2006). Although colonoscopy every 10 years
is considered to be the preferred screening method, it is imperfect because of variable
quality of screening colonoscopy under community-based practice conditions.
As the use of colonoscopy screening increases, the need for measurement of
colonoscopy quality is inevitable to ensure quality in the performance of colonoscopies.
Generally, the cecal intubation rate is most commonly studied. However, this is a very
limited measure of quality, and widespread poor quality of colonoscopy performance
continues to limit the CRC prevention potential.
Adenoma detection and removal is the mechanism of conferring CRC prevention
and is the main goal of colonoscopy, and should be a key indicator for assessing
colonoscopy quality. Among endoscopists a wide range of the adenoma detection rate
(ADR) has been documented (Millan 2008, Barclay 2006, Wilkins 2009, Rex 2001). This
implies that the quality of colonoscopies varies widely, which could reduce its efficacy in
CRC protection. A meta-analysis of 12 studies focusing on colonoscopies performed by
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primary care physicians (PCPs) with a total of 18,292 patients found an adenoma
detection rate of 28.9%. The authors concluded that colonoscopy performance by PCPs
can meet the professional, societies’ recommended standards (Wilkins 2009). The
association between colonoscope withdrawal times and adenoma detection rates was also
studied. Barclay (2006) reported that physicians who had a mean withdrawal time less
than 6 minutes (when no polyp was found) have an adenoma detection rate of 11.8%,
while it was 28.3% for those with a mean withdrawal time of more than 6 minutes. This
statistically significant difference persists in the next level of quality, the mean number of
adenomas per subject, which were 0.17 vs. 0.61, respectively. Rex et al (2001)
videotaped 10 procedures performed by 2 colonoscopists and got them reviewed/scored
by 4 experts based on four quality criteria related to colonoscopic withdrawal technique.
They reported that technique does matter to the adenoma miss rate, which could be
further associated with the potential cancer protection efficacy of colonoscopy screening.
There is concern about colonoscopy quality because of the variable results and outcomes
in terms of CRC prevention in the literature. Also, colonoscopy is a physician-dependent
procedure. To make sure that physicians are doing a good job is more important than how
many they have carried out.
In this study, our setting is a community-based facility, which has followed a
uniform protocol for almost all but not all physicians for 12 years. To evaluate the
protocol elements, we explore the association between the quality of colonoscopy
outcomes and two protocol elements, the 2-person technique pioneered by this center,
and sedation type.

3

1.2 Objectives
The aim of this study was to evaluate the quality of colonoscopies. Of the risk
factors which impact colonoscopy performance, our variables of interest were the clinical
procedure protocol type and the sedation type. We tested the impact of the protocol type
and the sedation type on the polyp/adenoma detection rate, the mean number of
polyps/adenomas detected, polyp size, polyp location, and the procedure time.
We hypothesized that colonoscopy quality may be enhanced by applying the 2person technique protocol relative to solo performance, and with deep sedation by
propofol relative to the conventional Midazolam-meperidine combination.
The hypotheses tested are:
1. The screening colonoscopy quality of physicians using the 2-person technique yields
more adenomas than with solo performers.
2. The screening colonoscopy quality of procedures with deep sedation by propofol
yields more adenomas than with the conventional Midazolam-meperidine
combination.
1.3 Significance of the research and methodology
Although colonoscopy is considered to be the reference gold standard against
which the sensitivity of other colorectal cancer screening tests is compared, it is not
perfect. Most of the evidence about the sensitivity of a colonoscopy comes from
experienced examiners conducting study colonoscopies in research settings without
detailed documentation on the protocol followed.
The innovative protocol at the community-based endoscopy center (hereafter
referred to as “Study Center” or “Center”) has the following unique features: a) a hands4

on 2-person technique, in which the endoscopy technician advances the colonoscope
while the physician manipulates the scope tip for polyp search and removal, b) propofol
sedation to substitute the conventional midazolam-meperidine (MM) combination
sedation starting in April 2006, and c) gradual insertion and withdrawal with polyp search
and removal during both phases to maximize coverage of the colonic mucosal surface.
The hands-on 2-person technique method avoids missing polyps due to physician's motor
fatigue, confers the dexterity of two “right” hands for polyp search and removal, and
ensures more persons (at least 3 persons, the third being the note taker ) watching the
video screen for polyps (avoiding visual error). Of these elements, item (a) was not
followed by experts and some specialists, which enables study of the contribution of the
hands on 2-person technique. Item (b), propofol sedation was implemented from April
2006 onwards, enabling pre- and post-comparison to assess the role of propofol sedation.
This research aims to contribute to the literature by:
1.

Using clinical data for the analysis

2.

Studying a state-of-the-art colonoscopy protocol, which has been applied for over 10
years

3.

Identifying the effect of protocol elements on screening colonoscopy quality

4.

Analyzing differences in adenoma detection rates by sedation type and number of
persons engaged in procedure performance.

1.4 Limitations
1.

This clinical dataset is from a single endoscopy center in South Carolina, as such the
observed findings may not generalize to the other settings.
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2.

Due to the strict implementation of a uniform protocol at this center, the vast
majority of the procedures were under state-of-the-art protocol. Only 2% of the
procedures were performed using the conventional industry practice of a one-person
technique, compared to 98% of procedures performed with the 2-person technique
distributed across 57 physicians. Therefore the observed results may not generalize
to all physicians using the 1-person technique.

1.5 Conclusions
This study finds that an innovation of a hands-on 2-person technique is highly
associated with superior colonoscopy performance and lesion detection outcomes. By
every sensitive measure, the results with the 2-person technique are superior and
consistent across measures. Regarding sedation type, we find that while there is a
suggestion of a positive association of propofol sedation with improved lesion detection
and clearance as measured by sensitive indicators, the results did not attain statistical
significance except in respect of one indicator, the advanced adenoma detection rate.
Another important indicator for logistic reasons is the procedure time. Because propofol
induces rapid and deep sedation, as anticipated the study showed a mean reduction in
procedure time adjusted for all other variables that may impact procedure time. Our
findings suggest that propofol sedation may contribute marginally to improved
colonoscopy quality. Our study also finds that quality improvement efforts may be more
productive if focused on measures to improve patients’ bowel preparation status through
efforts directed at patients, for example, through patient navigation. Regarding propofol
sedation itself, our findings indicate that endoscopist’s decisions to adopt propofol
sedation should be guided by considerations of patient comfort and satisfaction, and of
6

the efficiency of endoscopist time utilization rather than an expectation of improved
lesion detection rates. Our study does not provide support for adoption of propofol
sedation for the purpose of improving the colorectal cancer prevention effectiveness of
colonoscopy screening.
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Chapter 2

LITERATURE REVIEW

This chapter reviews the related colorectal cancer screening literature and makes
the case for the significance of this study based on past research.
2.1 Overview of colorectal cancer in the United States
2.1.1

Incidence and mortality
Approximately 7.6 million people die of cancer each year. These deaths account

for 13% of all deaths, and 64% occur in the developing countries. The burden of cancer is
increasing both in the developed and developing countries due to the growth of
population, aging, and changes in lifestyle, especially for the cancer-associated behaviors,
such as obesity, smoking, and adoption of Western-style diets. (Globocan (IARC) 2008,
WHO 2008, Jemal 2011). Colorectal cancer (CRC) is one of the most common cancers
and the leading cause of death in the U.S. since the late 1990s. The incidence of
colorectal cancer was 51.8 per 100,000 of the U.S. population in 1999 and the ageadjusted 2009 rate decreased to 44.7 per 100,000 in 2009. The death rate was 20.5 per
100,000 in 1999 and age-adjsuited rate in 2009 was 16.9 per 100,000 (SEER 1990-2010).
About 140,000 new cases and 55,000 deaths occur each year in the US (Wingo et al
1995). Although the incidence rate and death rate are decreasing, CRC has remained a
leading cancer on both incidence and deaths in the past two decades (USCS, CDC). The
incidence rate of CRC rose between 1975 and 1985, since then the incidence rate had
8

steadily reduced except for a non-significant plateau during 1995-1998. In 2008,
the incidence rate of CRC for men was 50.98 per 100,000 people and 39.64 per 100,000
people for women. The goal of Healthy People 2020 is to reduce CRC incidence to 38.6
per 100,000 people by 2020 (NCI 2012).
The significance of CRC is reflected both in the population affected and the
rankings. Globally, in 2008, about 1.2 million new cases and 608,700 deaths occurred
due to colorectal cancer (Globocan (IARC) 2008). It was found to be most prevalent in
Oceania, Europe, and North America (Globocan (IARC) 2008). In 2010, an estimated
142,570 new CRC cases, 9.32% of all cancer new cases occurred in the United States. An
estimated 51,370 people (9% of all cancer deaths) died from colorectal cancer (Jemal
2010, ACS 2010). The incidence and mortality rates of CRC rank as the 3rd most
frequent for both sexes (Jemal 2010, ACS 2010). The overall cost of cancer as estimated
by the National Institutes of Health was $263.8 billion, 9% for CRC amounts to about
$23.74 billion. Among these costs, $9.25 billion is for health expenditure, $1.88 billion is
for lost productivity due to illness, $12.61 billion is for lost productivity due to premature
death (ACS 2010).
The lifetime risk of an individual being diagnosed with CRC has been estimated
to be 5.42% for invasive CRC, and 5.73% if in situ CRC is included (SEER 1975-2004).
The lifetime risk of dying from CRC is 2.20% in the U.S. The overall 5-year survival rate
is 64%. It is 89-90% in persons with localized disease, 68-69% in persons with regional
spread, and only 10-11% in those with distant metastases (Ries et al 2007; SEER Cancer
Statistics Review 1975-2004). Even though the risk of CRC diagnosis or death exists, the
survival rate of CRC is relatively high when diagnosed early. Almost 90% of those with
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early CRC diagnosis survive for 5 years. But it is predicated upon early detection.
Furthermore CRC can be prevented. Reducing the colorectal cancer death rate is one of
the objectives of Healthy People 2020, the target rate being 14.5 deaths per 100,000. In
2008, the worldwide age-standardized mortality was 8.2%, accounted for approximately
0.6 million individuals, and the age-standardized incidence was17.2%, accounted for 1.24
million persons (Globocan (IARC) 2008).
2.2 Colorectal cancer prevention and the role of polyps
While the role of hyperplastic polyps in colon cancer is debated, benign
adenomatous polyps have been documented to be the precursor for most cases of colon
cancer, and polyps increase with age (Correa et al 1977, Rickert et al 1979). Detecting
and removing adenomatous polyps is effective in reducing the incidence and mortality of
CRC. Within polyps the proportion of villous architecture (showing rapid growth) is
positively associated with the size of adenomatous polyps and, furthermore, the potential
of having malignant characteristics (Rickert et al 1979). Evidence shows that
adenomatous polyps smaller than 10mm in diameter are rarely found to be cancer. The
villous architecture component is more likely to be found in adenomatous polyps larger
than 10mm (Enterline et al 1962, Morson 1974, Muto et al 1975, Spjut et al 1977).
According to Surveillance Epidemiology and End Results 17 (SEER-17), which
captures cancer data in 17 metropolitan/rural regions (San Francisco, Connecticut, Detroit,
Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles,
Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky,
Louisiana and New Jersey) 2002-2004, the lifetime risk of being diagnosed with CRC is
lowest in American Indians/Alaskan Natives (4.27% for invasive CRC and 4.45% for
10

invasive and in-situ CRC), followed by Hispanics (4.82% for invasive CRC and 5.08%
for invasive and in-situ CRC), and highest in Asians/Pacific Islanders (5.58% for invasive
CRC and 5.83% for invasive and in-situ CRC). The lifetime risk of dying from CRC is
lowest in American Indians/Alaskan Natives at 1.86%, followed by Hispanics at 1.92%,
and is highest in Blacks at 2.42% (Ries et al 2007). The pattern of lifetime risks between
ethnics of being diagnosed with CRC mirrors the pattern of lifetime risk of dying from
CRC.
Polyps in the colon are associated with different histology types. Some types of
polyps are more likely to be found in the left colon while others were not. Hyperplastic
polyps are most commonly found in the rectum – 86.1% of total polyps. Neoplastic
adenomas are the second most common, and both increase with age and are more
prevalent in men (Williams et al 1982). Although there is no consistent relationship
between the size of adenomas and age, as age increases, adenomas larger than 1 cm in
diameter are more prevalent. Sessile adenomas are more prevalent in the cecum, while
pedunculated adenomas had an increasing prevalence in the distal colon and were most
prevalent in the sigmoid colon (Williams et al 1982) While the role of hyperplastic
polyps in colon cancer is debated, benign adenomatous polyps have been documented to
be the precursor for most cases of colon cancer, and polyps increase with age (Correa et
al 1977, Rickert et al 1979). Detecting and removing adenomatous polyps is effective in
reducing the incidence and mortality of CRC. Within polyps the proportion of villous
architecture (showing rapid growth) is positively associated with the size of adenomatous
polyps and, furthermore, the potential of having malignant characteristics (Rickert et al
1979). Evidence shows that adenomatous polyps smaller than 10mm in diameter are
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rarely found to be cancer. The villous architecture component is more likely to be found
in adenomatous polyps larger than 10mm (Enterline et al 1962, Morson 1974, Muto et al
1975, Spjut et al 1977).
According to Surveillance Epidemiology and End Results 17 (SEER-17), which
captures cancer data in 17 metropolitan/rural regions (San Francisco, Connecticut, Detroit,
Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles,
Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky,
Louisiana and New Jersey) 2002-2004, the lifetime risk of being diagnosed with CRC is
lowest in American Indians/Alaskan Natives (4.27% for invasive CRC and 4.45% for
invasive and in-situ CRC), followed by Hispanics (4.82% for invasive CRC and 5.08%
for invasive and in-situ CRC), and highest in Asians/Pacific Islanders (5.58% for invasive
CRC and 5.83% for invasive and in-situ CRC). The lifetime risk of dying from CRC is
lowest in American Indians/Alaskan Natives at 1.86%, followed by Hispanics at 1.92%,
and is highest in Blacks at 2.42% (Ries et al 2007). The pattern of lifetime risks between
ethnics of being diagnosed with CRC mirrors the pattern of lifetime risk of dying from
CRC.
Polyps in the colon are associated with different histology types. Some types of
polyps are more likely to be found in the left colon while others were not. Hyperplastic
polyps are most commonly found in the rectum – 86.1% of total polyps. Neoplastic
adenomas are the second most common, and both increase with age and are more
prevalent in men (Williams et al 1982). Although there is no consistent relationship
between the size of adenomas and age, as age increases, adenomas larger than 1 cm in
diameter are more prevalent. Sessile adenomas are more prevalent in the cecum, while
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pedunculated adenomas had an increasing prevalence in the distal colon and were most
prevalent in the sigmoid colon (Williams et al 1982) While the role of hyperplastic
polyps in colon cancer is debated, benign adenomatous polyps have been documented to
be the precursor for most cases of colon cancer, and polyps increase with age (Correa et
al 1977, Rickert et al 1979). Detecting and removing adenomatous polyps is effective in
reducing the incidence and mortality of CRC. Within polyps the proportion of villous
architecture (showing rapid growth) is positively associated with the size of adenomatous
polyps and, furthermore, the potential of having malignant characteristics (Rickert et al
1979). Evidence shows that adenomatous polyps smaller than 10mm in diameter are
rarely found to be cancer. The villous architecture component is more likely to be found
in adenomatous polyps larger than 10mm (Enterline et al 1962, Morson 1974, Muto et al
1975, Spjut et al 1977).
According to Surveillance Epidemiology and End Results 17 (SEER-17), which
captures cancer data in 17 metropolitan/rural regions (San Francisco, Connecticut, Detroit,
Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles,
Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky,
Louisiana and New Jersey) 2002-2004, the lifetime risk of being diagnosed with CRC is
lowest in American Indians/Alaskan Natives (4.27% for invasive CRC and 4.45% for
invasive and in-situ CRC), followed by Hispanics (4.82% for invasive CRC and 5.08%
for invasive and in-situ CRC), and highest in Asians/Pacific Islanders (5.58% for invasive
CRC and 5.83% for invasive and in-situ CRC). The lifetime risk of dying from CRC is
lowest in American Indians/Alaskan Natives at 1.86%, followed by Hispanics at 1.92%,
and is highest in Blacks at 2.42% (Ries et al 2007). The pattern of lifetime risks between
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ethnics of being diagnosed with CRC mirrors the pattern of lifetime risk of dying from
CRC.
Polyps in the colon are associated with different histology types. Some types of
polyps are more likely to be found in the left colon while others were not. Hyperplastic
polyps are most commonly found in the rectum – 86.1% of total polyps. Neoplastic
adenomas are the second most common, and both increase with age and are more
prevalent in men (Williams et al 1982). Although there is no consistent relationship
between the size of adenomas and age, as age increases, adenomas larger than 1 cm in
diameter are more prevalent. Sessile adenomas are more prevalent in the cecum, while
pedunculated adenomas had an increasing prevalence in the distal colon and were most
prevalent in the sigmoid colon (Williams et al 1982) While the role of hyperplastic
polyps in colon cancer is debated, benign adenomatous polyps have been documented to
be the precursor for most cases of colon cancer, and polyps increase with age (Correa et
al 1977, Rickert et al 1979). Detecting and removing adenomatous polyps is effective in
reducing the incidence and mortality of CRC. Within polyps the proportion of villous
architecture (showing rapid growth) is positively associated with the size of adenomatous
polyps and, furthermore, the potential of having malignant characteristics (Rickert et al
1979). Evidence shows that adenomatous polyps smaller than 10mm in diameter are
rarely found to be cancer. The villous architecture component is more likely to be found
in adenomatous polyps larger than 10mm (Enterline et al 1962, Morson 1974, Muto et al
1975, Spjut et al 1977).
According to Surveillance Epidemiology and End Results 17 (SEER-17), which
captures cancer data in 17 metropolitan/rural regions (San Francisco, Connecticut, Detroit,
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Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles,
Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky,
Louisiana and New Jersey) 2002-2004, the lifetime risk of being diagnosed with CRC is
lowest in American Indians/Alaskan Natives (4.27% for invasive CRC and 4.45% for
invasive and in-situ CRC), followed by Hispanics (4.82% for invasive CRC and 5.08%
for invasive and in-situ CRC), and highest in Asians/Pacific Islanders (5.58% for invasive
CRC and 5.83% for invasive and in-situ CRC). The lifetime risk of dying from CRC is
lowest in American Indians/Alaskan Natives at 1.86%, followed by Hispanics at 1.92%,
and is highest in Blacks at 2.42% (Ries et al 2007). The pattern of lifetime risks between
ethnics of being diagnosed with CRC mirrors the pattern of lifetime risk of dying from
CRC.
Polyps in the colon are associated with different histology types. Some types of
polyps are more likely to be found in the left colon while others were not. Hyperplastic
polyps are most commonly found in the rectum – 86.1% of total polyps. Neoplastic
adenomas are the second most common, and both increase with age and are more
prevalent in men (Williams et al 1982). Although there is no consistent relationship
between the size of adenomas and age, as age increases, adenomas larger than 1 cm in
diameter are more prevalent. Sessile adenomas are more prevalent in the cecum, while
pedunculated adenomas had an increasing prevalence in the distal colon and were most
prevalent in the sigmoid colon (Williams et al 1982).
2.3 Identifying at-risk population
2.3.1

Average-risk persons

15

Incidence and death rates of CRC increase with age. In the US population, the
incidence rate exceeds 100 per 100,000 from the 60-64 age group, and the death rate
accelerates from the 75-79 age group (SEER Cancer Statistics Review, 1975-2008). In
South Carolina, the incidence rate of more than 10/100,000 is observed starting in the 5559 age group, and death rate exceeds 10/100,000 in the 75-79 age group for the mortality
rate (SC SCAN). Figure 2.1 – Figure 2.4 show the incidence rate and the mortality rate of
CRC for South Carolina population and the trend-line from 1996 to 2009 (SC SCAN):
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Cancer Incidence: Full (Research) File
For South Carolina Residents
County: All Counties in South Carolina
Primary Cancer Sites: Colorectal (colon, rectum, and rectosigmoid)
Age
35-39 40-44 45-49 50-54 55-59 60-64 65-69 70-74 75-79 80-84 85+
Year Rates Rates Rates Rates Rates Rates Rates Rates Rates Rates Rates
1996 10.5 19.1 36.1 69.6 100.7 156.2 190.8 275.5 316.5 366.7 429.6
1997 10.7 17.6 39.2 62.4 109.3 161.5 187.3 280.2 334.4 320.3 437.9
1998 13.8 18.2 38.7 64.4 110.6 161.9 214.0 302.2 344.0 418.1 402.5
9.2 18.5 35.8 72.9 108.2 154.2 233.0 279.1 342.2 336.2 407.0
1999
8.6 21.8 45.6 65.2 108.1 161.2 210.6 274.9 321.3 414.1 402.8
2000
2001 10.4 24.1 44.5 63.4 101.7 157.6 199.4 285.2 318.8 387.5 383.2
2002 11.3 23.5 45.1 70.9 105.4 161.2 233.1 283.1 326.6 362.5 364.0
2003 13.2 23.5 38.8 73.6 117.8 156.8 245.2 291.8 302.0 335.6 359.6
2004 16.2 27.3 34.5 79.2 110.1 138.0 216.7 259.4 323.1 346.1 370.4
2005 10.0 15.4 32.5 75.1 107.7 143.6 200.8 243.3 281.1 346.6 328.3
2006 14.3 21.2 41.9 66.0 91.0 131.1 195.3 221.9 259.8 280.2 256.0
2007 10.7 17.6 39.4 77.4 92.4 124.0 179.6 201.2 256.4 244.7 291.2
8.9 20.1 39.4 68.5 84.4 115.1 159.0 186.4 228.8 260.2 277.4
2008
8.4 16.9 40.7 59.1 77.1 108.1 139.3 166.9 206.0 216.8 244.0
2009
*Rate: Crude Rate calculated per 100,000 population
Figure 2-1 Colorectal cancer incidences in the past decade
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Figure 2-2 The trend line of colorectal cancer incidence in the past decade
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Cancer Mortality
For South Carolina Residents
County: All Counties in South Carolina
Primary Cancer Sites: Colorectal (colon, rectum, and rectosigmoid)
Age
35-39 40-44 45-49 50-54 55-59 60-64 65-69 70-74 75-79 80-84 85+
Year Rates Rates Rates Rates Rates Rates Rates Rates Rates Rates Rates
#
6.6 10.9 14.5 34.2 42.9 66.4 106.8 108.8 182.4 270.9
1996
#
5.1 12.0 18.9 33.2 40.7 63.8 91.2 123.0 157.6 246.7
1997
#
5.3
8.0 19.2 30.6 37.8 58.1 87.0 124.9 178.0 230.3
1998
1999
2000
2001
2002

#
#
#
#

6.8
#
8.6
7.9

10.3
10.4
11.5
12.9

21.4
15.8
16.9
18.5

30.1
37.0
23.8
22.8

49.6
41.9
39.5
54.7

67.6 80.4 123.1 166.5
61.7 101.8 121.5 185.2
75.7 79.3 129.9 153.5
57.6 79.5 112.7 149.3

252.8
268.6
229.2
228.9

2003

#

7.3

13.4

14.7

26.7

46.8

57.5

84.4 102.6 161.6

222.7

2004
2005
2006
2007
2008

#
#
#
#
#

6.3
5.7
4.7
#
5.5

6.8
12.7
10.0
8.7
11.7

18.2
15.1
17.1
13.7
18.2

27.8
26.1
30.8
25.3
24.6

32.6
37.5
45.1
44.3
27.9

51.8
59.2
65.9
50.7
49.6

67.0
60.6
74.0
67.8
78.1

136.4
145.3
134.0
84.4
110.2

194.9
231.0
158.9
172.4
195.0

2009

#

#

10.9

17.9

26.2

35.4

40.4

58.8

81.0 118.3

167.0

*Rate: Crude Rate calculated per 100,000 population
Figure 2-3 Colorectal cancer mortalities in the past decade
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106.1
106.5
102.1
113.4
82.4

Figure 2-4 The trend line of colorectal cancer mortality in the past decade
The U.S. Preventive Services Task Force (USPSTF), the American Cancer
Society (ACS), the National Comprehensive Cancer Network (NCCN), and the U.S.
Multi-Society
ety Task Force (MSTF) recommend periodic screenings of the average-risk
average
population to prevent CRC, which includes men and women aged over 50 years with no
history of adenomas, colorectal cancer, inflammatory bowel disease, and family history
(USPSTF 2008, Levin 2008, NCCN 2012). The USPSTF recommends routine CRC
screenings with fecal occult blood test (FOBT), sigmoidoscopy, or colonoscopy for
adults aged 50-75
75 years. Between 76 and 85 years old, routine screening is not
recommended, but it can be provided aas required based on specific clinical
considerations. For patients older than 85 years, CRC screening is not recommended
(USPSTF, 2008).
2.3.2

High-risk persons
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Asymptomatic individuals with a family history are categorized as high-risk for
colorectal cancers. This group of persons is recommended to have screening at an earlier
age than the average-risk group. The American College of Gastroenterology (ACG), the
ACS and the NCCN have updated standards of the high-risk population and the
recommended screening guidelines (Levin 2008, Rex 2009, NCCN 2012):
Persons with single first-degree relative with CRC or advanced adenoma
diagnosed at age < 60 years or two first-degree relatives with colorectal cancer
or advanced adenomas will be considered as high risk population, and are
recommended to have colonoscopy screening every 5 years beginning at the age
of 40 years, or 10 years younger than the age at diagnosis of the youngest
affected relative. Or, with personal history of adenoma/sessile serrated polyps,
colon cancer, or inflammatory bowel disease (i.e., ulcerative colitis, Crohn’s
disease) additional screenings are recommended.
Other persons defined as high-risk have one of two hereditary syndromes (Byers 1997):
•

Familial Adenomatous Polyposis syndromes (FAP)
People with this condition develop hundreds of colorectal polyps and will almost
certainly develop colorectal cancer unless the colon is removed.

•

Hereditary Non-Polyposis Colorectal Cancer syndromes (HNPCC)
HNPCC has been classically defined as colorectal cancer in three or more family
members, two of whom are first-degree relatives of the third, involving people in at
least two generations, and with at least one person diagnosed with colorectal cancer
before age 50 years.
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HNPCC, also known as the Lynch syndrome, accounts for approximately 5% of
new cases of CRC each year (Winawar 1997).
Persons with a family history of hereditary syndromes, with relatives who
received diagnoses of colorectal cancers at an early age, with two or more affected
relatives, or with persistent ulcerative colitis have a high risk of colon cancers. The risk is
especially high among younger persons (40-59 years old), but not associated with
individuals after 60 (Fuchs et al 1994). Other principal risk factors include a history of
colorectal cancers or adenomas in a first-degree relative, a personal history of large
adenomatous polyps or colorectal cancers, and a prior diagnosis of endometrial, ovarian,
or breast cancers (Rustogi 1994, USPSTF (Baltimore), 1996). Based on an ACS report in
1981, the high-risk population was described as (Eddy, 1981):
“Persons with familial polyposis, Gardner’s syndrome, ulcerative colitis, a
history of polyps or prior colon cancer, and a family history of cancer of the
colon or rectum”.
2.4 Early CRC detection and management
CRC is highly curable if detected in an early stage through routine screenings of
the colon/rectum. When polyps/adenomas are detected and removed in the early
developmental course, the 5-year relative survival rate is 90% (CDC 2011).
Among the screening methods, the effectiveness of the screening tool for
detecting neoplasia lesions is critical. Theoretically, sensitivity is defined as the ability of
the tool to identify true positives among all positives. In case of CRC, sensitivity is the
percentage of people who have neoplastic lesions who are correctly identified by the
screening tool as having the condition. Sensitivity is highest for colonoscopy, followed
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by flexible sigmoidoscopy, followed by fecal tests, Hemoccult SENSA being the best
followed by fecal immunochemical test, and lowest for Hemoccult II (USPSTF 2008).
Specificity of the screening tool is defined as the ability to identify true negatives among
all negatives. In case of CRC, specificity is the percentage of people with no neoplastic
lesions who are correctly identified as clear. Specificity is highest for colonoscopy as
well, followed by flexible sigmoidoscopy, then Hemoccult II, which is also
approximately equal to fecal immunochemical test, and lowest for Hemoccult SENSA
(USPSTF 2008).
One randomized clinical trial study in 1993 exploring the effect of FOBT
screenings on CRC mortality for up to 13 years of follow-up reported that the annual
FOBT group had the highest 13-year survival rate, with a 33% reduced mortality from
colon cancers compared to the control group, and almost double the reduction observed
in the biennial FOBT group (Mandel et al 1993). Although observational studies have
reported incidence/mortality reductions associated with screening colonoscopy and
polypectomy (Winawar et al 1993, Zauber et al 2012), less than half of the US screeningeligible population is covered by screening (Meissner et al 2006, Seeff et al 2004).
Research has shown the effect of early detection and the removal of precancerous lesions
through screening on CRC incidence and mortality reduction in the United States
(Edwards et al 2010, Center et al 2009, Chu et al 1994).
Less than 40% of colorectal cancers are detected at an early stage (CDC 2011).
According to the National Health Interview Survey (NHIS) in 2005, only 50% of U.S.
people aged 50 to 75 years had received a colorectal cancer screening. Colorectal cancer

23

screening take up rate remains low and there is still a big gap to fill given that the target
rate in the Healthy People 2020 is 70.5%.
Except for patients with bowel symptoms, the physician recommendation/referral
is a required precondition for CRC screenings. Although Medicare coverage of
colonoscopies since 2001 reduced the racial disparity in colonoscopy screenings between
older Whites and Blacks (Shih et al 2006), studies suggest that physician
recommendations are less frequent for Blacks than for Whites both in the general
population, and among Medicare beneficiaries (Klabunde et al 2006), which translates to
a lower screening rate among Blacks. The low take up rate and the disparity in the access
of screening could be a potential reason for Blacks having a relatively high CRC
incidence (Rex 2004, Daguise et al 2006).
2.5 History of CRC screening in the US
Before 1980, the American Cancer Society (ACS) recommended that people aged
over 40 years should be screened with the annual sigmoidoscopy. The digital proctoscope
and occult blood examinations were urged to be included in the regular health checkups
for adults over age 40 by the ACS (Eddy 1980). Based on an ACS report in 1981, those at
high risk were recommended to have more “frequent” and “intensive” examinations
starting at an earlier age (Eddy, 1981). In a June 1992 meeting, revisions were made by
the National Board of Directors of the American Cancer Society to the guidelines for
asymptomatic individuals (Levin et al 1992):
1.

Sigmoidoscopy, preferably flexible, for persons aged 50 and older, males and
females, every three to five years.
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2.

“Fecal Occult Blood Test (FOBT)” substituted for “stool guaiac slide test” every
year for individuals age 50 and over.
The ACS also made a revision to recommendations for the high-risk population at

this meeting in June 1992 (Table 2-1) (Levin & Murphy 1992):
1. If first-degree relatives have a CRC diagnosis at an age less than 55 years, a
colonoscopy or a double-contrast barium enema (DCBE) was recommended every 5
years starting at age 35 – 40 years.
2. If family members have a history of familial adenomatous polyposis, early flexible
sigmoidoscopy is required.
3. If family members have a history of hereditary nonpolyposis CRC, early initiation
and more intense colonoscopy screening is required.
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Table 2-1 American Cancer Society Recommendations for the Early Detection of Colon
Cancer in Asymptomatic Persons (1992)
Test or Procedure
Population
Sex
Age
Frequency
Sigmoidoscopy, Perferably Flexible Male & Female 50 and over Every 3 to 5 years
Fecal Occult Blood Test
Male & Female 50 and over
Every year
Digital Rectal Examination
Male & Female 40 and over
Every year
Source: Levin B, Murphy GP. Revision in American Cancer Society Recommendations for the
Early Detection of Colorectal Cancer. CA Cancer J Clin. 1992; 42(5): 296-9.

Although FOBT alone is shown to have a significant effect on CRC mortality
reduction (Mandel 1993), the 1997 ACS Clinical guidelines (Table 2-2) had an additional
recommendation of “sigmoidoscopy screening every 5 years to complement the annual
FOBT” (Byers 1997), due to later findings from RCT studies that about one third to one
half of mortality reduction observed from FOBT may be attributed to colonoscopies
(Lang 1994), and to substantial risk reduction conferred by sigmoidoscopies (Selby 1992,
Newcomb 1992). The ACS recommends sigmoidoscopy screenings every 5 years in
addition to the annual FOBT to intensively monitor the descending colon.
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Table 2-2 The 1997 ACS colorectal screening guidelines (Byers 1997)
Average risk people
Screening by either one of methods:
(Single first-degree relative
1. Annual FOBT with sigmoidoscopy every 5
diagnosed with CRC, or
years.
adenomas after age 50, or no first2. Annual FOBT with colonoscopy every 10
degree relative, or those without
years.
any personal or family history of
3. Annual FOBT with DCBE every 5 to 10
CRC or adenomas)
years.
Moderate risk people
1. Remove adenomatous polyp at the procedure,
(People who are diagnosed as
followed by surveillance in 3 years.
having adenomatous polyps)
2. If the original polyp was smaller than
1cm/non-villous pathology and the 3-year
surveillance is negative, then back to average
risk pool.
3. If the original polyp was larger than 1cm or
villous pathology, the surveillance should be
repeated every 5 years.
High risk people
1. If FAP confirmed, consider colectomy.
2. If HNPCC confirmed, colonoscopy every 2
years until age 40, every year thereafter.
In 1996, the USPSTF first published the guidelines for colorectal cancer
screenings with these screenings were fecal occult-blood tests or sigmoidoscopies
(USPSTF (AHRQ), 1996). Two years later, these screenings were covered by Medicare
(http://healthservices.cancer.gov/seermedicare/considerations/testing.html); in 2000, most
health plans covered at least one of four recommended colorectal cancer screening tests
(Klabunde et al 2004). Medicare covered colonoscopies starting from 2001 (Shih 2006).
In 2002, the USPSTF found strong evidence on the effectiveness of several screening
methods in reducing mortality, such as 5-year sigmoidoscopy alone or in combination
with the FOBT. However, the evidence that colonoscopies reduce mortality was still
insufficient. The USPSTF also concluded that evidence was insufficient to assess the
benefits and harms of computed tomographic colonography and fecal DNA testing as
screening modalities for colorectal cancer (USPSTF 2002). In 2008, the USPSTF updated
the recommendations for CRC screenings, recommending annual FOBT, 5-year
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sigmoidoscopy, or colonoscopy, beginning at age 50 years and continuing until age 75
years (USPSTF 2008). In contrast to the 2002 USPSTF recommendation statements, the
USPSTF updated the recommended screening eligibility from “individuals age 50 years
and older” to “50 years and continuing to 75 years.” Also, high-sensitivity FOBTs,
sigmoidoscopies with interval FOBTs, or colonoscopies were recommended replacing the
un-prioritized recommendations in 2002. For CT colongraphy and fecal DNA, the
USPSTF concluded to maintain that there is insufficient evidence for recommendation
(USPSTF 2008).
2.6 CRC screening methods
Screening tests for CRC prevention basically are categorized into 2 types, the
fecal tests (such as the Fecal Occult Blood Test (FOBT)), and the full or partial structure
tests, such as Digital Rectal Examination (DRE), sigmoidoscopy, barium enema,
Computed Tomographic (CT) colonography, and colonoscopy.
There is insufficient evidence to determine which of these screening methods is
preferable, or whether the combination of FOBT and sigmoidoscopy produces greater
benefits than either test alone. Furthermore, there is insufficient evidence to recommend
for or against routine screenings with digital rectal examinations, barium enemas, or
colonoscopies, although recommendations against these screenings in average-risk
persons may be made on other grounds (USPSTF (Baltimore) 1996). The USPSTF
recommended 3 screening methods: 1) annual high-sensitivity fecal occult blood testing,
2) sigmoidoscopy every 5 years combined with a high-sensitivity fecal occult blood test
every 3 years, and 3) screening colonoscopy at intervals of 10 years. Adherence to any of
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the 3 methods is considered effective in detecting advanced adenomatous polyps and
cancers at an early stage (USPSTF 2008).
The three CRC screening methods commonly used are – fecal occult blood test
(FOBT), flexible sigmoidoscopy, and colonoscopy. All tests lead to colonoscopies if they
are positive, which permits the visual detection of early stage cancers and removal of
adenomatous polyps simultaneously during the procedure (Denis et al 2011).
2.6.1

Fecal occult blood test (FOBT) / Stool blood test
Stool blood tests are broadly known as guaiac fecal occult blood test (gFOBT)

because the tests are designed to detect the occult blood in stool through guaiac method.
CRC can be detected by finding occult blood in the stool, which is not readily visible.
Also, the bleeding caused by cancers or advanced adenomatous polyps depends on the
lesion size, friability, and location, and blood may might not be detected by the naked
eye. But the problem with the stool blood test is its accuracy, because blood is unevenly
distributed in the stool and the bleeding is intermittent. Further there are substances other
than hemoglobin that can produce false positive results, such as iron in the diet (Eddy
1981). CRC screening cannot rely solely on FOBT results, but can use FOBT results as a
preliminary test.
Besides false negatives caused by intermittent bleeding, faulty FOBT tests caused
by diet should be avoided. Therefore, individuals are advised certain dietary limitations
for two days before the stool blood test to avoid false positive results (most commonly
caused by iron supplements and red meat) and false negative results (Vitamin C and
citrus fruits) (Eddy 1981, Jaffe et al 1975, Garrick et al 1977).
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Positive reactions on guaiac-impregnated cards, the most common form of testing,
signal the presence of bleeding from premalignant adenomas and early-stage colorectal
cancers (USPSTF (Baltimore) 1996).The stool blood test is far less likely to help prevent
cancers compared to invasive tests such as flexible sigmoidoscopy or colonoscopy. To be
effective, FOBT must be repeated at a regular interval, otherwise the protection is nil.
When the test is positive, an invasive test, such as a colonoscopy, is needed (Levin et al
2008). If patients are not willing to repeat the FOBT or take the invasive test when the
FOBT is abnormal, FOBT is ineffective and should not be recommended (Levin et al
2008). FOBT has very low test sensitivity (especially a single test) for detecting
adenomas, and has a reasonable sensitivity for detecting colorectal cancers. However,
regarding the program sensitivity (serial tests over time in a program), it is relatively
high. Therefore, repeating testing each year is a very important key for ensuring the
quality of FOBT (Levin et al 2008). In a randomized clinical trial of FOBT screening
with a 13-year follow-up period, the results showed 33% reduction in colorectal cancer
mortality, and better 5-year survival for those with annual FOBT screening (Mandel et al
1993).
Hemoccult, is the trademark for a guaiac reagent strip test for occult blood.
Before the development of the Hemoccult, several chemical tests were used for blood
stool test. These procedures require patients to have several samples of stool in cups or
jars, which stand in the refrigerator for a couple days, which then have to be physically
transported to the physician’s office or the hospital. It is unpleasant for patients and for
medical professionals who open the sample by the time of examination. Another problem
for the guaiac fecal occult blood test is that guaiac is very sensitive to heat and light.
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Due to the issue of intermittent bleeding of polyps and cancers, Hemoccult II
Slides are designed so that patients can collect serial specimens at home from bowel
movements over three days. This increases the probability of detecting hidden blood from
polyps and cancer. After the patient prepares the Hemoccult II SENSA elite test, it may
be returned in person or by mail to the laboratory, hospital or medical office for testing
and interpretation. The test consists of two main components: 1) the test cards containing
guaiac paper, 2) The Developer, a developing solution containing a stabilized mixture of
less than 4.2% hydrogen peroxide and 80% denatured ethyl alcohol and enhancer in an
aqueous solution. Research has shown that the rehydrated Hemocuult II slides show a
high sensitivity in detecting CRC (92.2%) but disappointingly low specificity (90.4%),
which causes too many colonoscopy referrals and produces high corresponding costs
(Byers 1997, Mandel 1993).
A relatively new method for the fecal test is the fecal immunochemical test (FIT).
FITs are highly specific in detecting human blood and in eliminating the dietary
restrictions. Research on the sensitivity and specificity of detecting the advanced
adenomas, however, is disappointing. Allison’s (2007) study of three Northern Kaiser
Permanente Medical Centers between April 1997 and October 1999 revealed that the
sensitivity and specificity for advanced neoplasms in the left colon were only followed by
colonoscopies within 2 years after the FOBT screening (29.5% for sensitivity and 97.3%
for specificity).
2.6.2

Digital rectal examination (DRE)
The digital rectal examination is of limited value as a screening test for colorectal

cancer. The examining finger, which is only 7-8 cm long, has limited access even to the
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rectal mucosa, which is 11cm in length, where about one-sixth of the colon cancers occur
(Eddy 1981, USPSTF (Baltimore) 1996).
A digital (finger) rectal examination is used to check for problems with organs or
other structures in the pelvis and the lower belly. During the examination, the doctor
gently puts a lubricated, gloved finger of one hand into the rectum. The doctor may use
the other hand to press on the lower belly or pelvic area (Healthwise 2010). The results
for DRE can be normal, where there are no problems such as organ enlargements or
growths are felt, and vice versa. Growths such as hemorrhoids, polyps, tumors, or
abscesses may be found in the lower rectum. Breaks in the skin around the anus (anal
fissures) may be found; problems of the bladder may also be felt (Healthwise 2010). The
DRE alone is not effective to check for colorectal cancers. If problems are found during a
DRE, more advanced tests are needed, such as a sigmoidoscopy or a colonoscopy
(Healthwise 2010).
There are no formal studies/reports for the effectiveness of DRE since the costs
are small and its high safety feature, any benefits can be considered as worthwhile, the
only potential harm is it might produce a false-positive results leading to other structure
tests, such as sigmoidoscopies (Eddy 1980). Also, the DRE is not as effective as
sigmoidoscopy because neoplasms can be hidden by mucus or any residual substances
even within the area reached by exploring fingers (Eddy 1981).
2.6.3

Sigmoidoscopy
The sensitivity and the diagnostic yield of sigmoidoscopy screening varies with

the type of instrument: the rigid (25cm) sigmoidoscope, the short (35cm) flexible
sigmoidoscope, and the long (60cm) flexible fiberoptic sigmoidoscope (USPSTF
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(Baltimore) 1996). The effectiveness of risk reduction for sigmoidoscopy has been
widely documented (Lang 1994, Selby 1992, Mewcomb 1992).
i.

Rigid sigmoidoscopy
The 25-cm rigid sigmoidoscopy was introduced in the 19th century but no longer

used since 1982 (Eddy 1980, Mandel et al 1993). Theoretically, it can cover up to 25 cm
of the colon, where about one-half to two-thirds of cancers and adenomatous polyps grow
(Eddy 1981). There are pros and cons of rigid sigmoidoscopes. It allows direct
visualization of the colon, biopsy, and removal of the suspicious lesions. Patient
discomfort and the risk of perforation of the colon are problems to be considered,
however (Eddy 1981). Due to patient discomfort and the development of new technology,
the rigid sigmoidoscopy is no longer used. A retrospective study in 1992 on the
effectiveness of rigid sigmoidoscopy showed that participants who had undergone one or
more rigid sigmoidoscopy examinations within the past 10 years had only 30% of the risk
of dying from distal colon or rectum cancers relative to those who did not (Selby 1992).
ii.

Flexible sigmoidoscopy
The 35-cm flexible sigmoidoscope can visualize about 50-75% of the sigmoid

colon and can detect about 50-55% of polyps (USPSTF (Baltimore) 1996). The 65-cm
flexible fiberoptic sigmoidoscope enables a longer range visualization of the colon,
however, the high cost and limited screening-only usage impedes its coverage in the
United States (Eddy 1981). Men had a higher uptake rate of sigmoidoscopy than women
(Meissner et al 2006). The detection rate of advanced neoplasia with sigmoidoscopy was
three times higher than FOBT in an Italian randomized controlled trial (RCT) study
(Segnan et al 2005). A randomized trial in the United Kingdom shows that a one-time
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flexible sigmoidoscopy of adults aged 55-64 years reduced the incidence of colorectal
cancer by 33%, and mortality by 43% (Atkin et al 2010).
Sigmoidoscopies can also produce false-positive results, primarily from polyps
detected that are unlikely to become malignant during the patients’ lifetime (USPSTF
(Baltimore) 1996). It turns out that the majority of asymptomatic persons with colonic
polyps discovered by routine sigmoidoscopic examinations will not develop into
clinically significant malignancies during their lifetime. For these patients, interventions
typically followed (i.e., biopsies, polypectomies, and frequent colonoscopies). Costly
procedures, anxiety provoking, and potential harms are unlikely to make up for the
clinical benefits of sigmoidoscopies (USPSTF(Baltimore), 1996). Flexible
sigmoidoscopy was considered too expensive and specialized only for early detection
usage (Eddy 1980).
Another disadvantage of sigmoidoscopy is the distribution of cancers in the colon.
Studies indicated that the proximal colon cancer accounts for a significant portion of the
colorectal cancers. The contribution of incident colon cancer in the proximal colon
beyond the examination zone of sigmoidscopy is about 27% to 45% (Dinning 1994,
Castiglione 1995, Lemmel 1996). The ratio of proximal cancer to total CRC is 0.338
among men and 0.421 among women (SEER CanQues 1973-2009).
A study explored the sites of primary CRC diagnosis from nine cancer registries
between 1978 and 1988. It concluded that older population (70 years and older) has the
greatest risk of CRC, and most commonly in the right colon (Rabeneck 2003). Although
the incidence of CRC has steadily declined since 1975 (NCI 2012) due to increasing
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aging population (65 years and older), the proportion of the population at risk of CRC is
expanding with aging of the US population (Rabeneck 2003).
2.6.4

Barium enema
Barium enema is one variant of X-ray examination, and is of two types, single

contrast barium enema (SCBE) and double contrast barium enema (DCBE).
Barium enema examinations have been shown to better identify most of the
advanced, most likely incurable, carcinomas of the colon instead of the early, potentially
curable carcinomas of the colon. Therefore, the routine use of barium enema
examinations is not reliable and is recommended for discontinuation in the diagnostic
evaluation of carcinomas of the colon (Gilbertsen et al 1979).
i.

Double Contrast Barium Enema (DCBE)
During this procedure, the physician inserts a tube into the rectum, fills in barium

sulfate, and drains its out, leaving a thin layer of barium on the wall of colon, and then air
is filled in to define the outline of the colon. Then X-ray images from various angles are
taken to better view the whole colon and detect abnormal growths (Byers 1997). A
positive result in DCBE should be followed by a colonoscopy or a sigmoidoscopy (Byers
1997).
ii.

Single Contrast Barium Enema (SCBE)
The difference between SCBE and DCBE is that the former fills the barium in the

colon to outline the colon for detecting abnormal growths. The procedure time for SCBE
is shorter than DCBE. SCBE is mostly performed for specific medical reasons or for
older people who may not be able to tolerate the more time-consuming and
uncomfortable DCBE procedure (Byers 1997).
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The performance of barium enema varies by section of colon, and highest in the
straight portions – descending colon (93%), transverse colon (89%), and ascending colon
(88%); followed by the askew portions – the splenic flexure (86%), the hepatic flexure
and the sigmoid flexure (83%). It is lowest in the globular portions – the rectum (77%)
and the cecum (75%). The average sensitivity for cancer is 83%. In addition, the DCBE
has better sensitivity than SCBE, with 0.78 being odds ratio of missed cancers (Rex,
Rahmani, Haseman 1997).
Overall, barium enemas are less expensive than colonoscopies. But colonoscopies
enable direct visualization of the colon and removal of the suspicious lesions directly for
biopsy with a one-time procedure if the bowel prepared properly. Colonoscopies have a
higher sensitivity and are least likely to miss cancers, with an odds ratio of 0.25 relative
to barium enema (Byers 1997, Rex, Rahmani, Haseman, 1997).
2.6.5

CT colonography
CT colonography also known as “virtual colonoscopy” or “X-ray colonoscopy”,

which is noninvasive and based on radio-imaging. Carbon dioxide gas is introduced into
the rectum to inflate the colon, and computer tomography pictures of the colon are taken
by a moving scanner. The pictures taken are integrated using computer programs to
create a two- or three-dimensional virtual viewing of the colon (Wilkins 2008; NDDIC
2008). Nationally, according to a report using the National Health Interview Survey
(NHIS) 2010, the use of CR colonography is extremely low (1.3%) (Shapiro 2010). CT
colonography shows high sensitivity and specificity for detecting large polyps (>10 mm)
but low sensitivity for smaller polyps. Pickhard and colleagues (2003) studied 1,233
asymptomatic individuals undergoing same-day CT colonography and colonoscopy using
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the segment unblinded method, which declares the findings of each section of the colon
after it is examined by colonoscopy. They reported a sensitivity of 93.8% and 96%
specificity on polyps of 10 or more millimeters; however, when polyps more than 6
millimeters were included the sensitivity reduced to 88.7%, and specificity to 79.6%.
Macari and colleagues (2005) using 2-dimensional views also reported the sensitivity of
CT colongraphy reduced significantly with polyp size (>10 mm: 100%, 6-9 mm: 52.9%,
1-5 mm: 11.5%).
Besides the effectiveness of CT colonography in identifying a polyp, a study in
2008 of 2,531 asymptomatic individuals from 15 facilities using per-patient analysis
showed that the sensitivity for polyps of 10 millimeters was 90% and 86% for specificity,
which is consistent with the previous literature. However, the positive predictive value of
CT colonography is 23% (with a high negative predictive value of 99%), which means
the accuracy of diagnosis is extremely low, and the ability of radiologists identifying
even the large polyps (>10mm) is an issue (Johnson 2008).
Interpreting CT colongraphy in non-academic environments has little evidence
and poor outcomes. Burlings et al. (2006) investigated the interpretation accuracy of 13
radiologists from seven non-academic facilities in comparison with that of trained
radiographic technicians and experienced academic radiologists. They showed that the
individual accuracy highly varies among 13 non-academic radiologists (range from 53%
to 93%). In addition, there are significant differences between these groups: the mean
accuracy is highest in experienced academic radiologists (88%), followed by nonacademic radiologists (75%), and lowest in trained radiographic technicians (56%).
Because of the low sensitivity in small and/or diminutive polyps, it is not a valuable
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method for the prevention of CRC. Also, the use of CT colonography has not been
recommended by USPSTF due to the insufficient evidence on its benefits and harms
(USPSTF 2008).
2.6.6

Colonoscopy
Evidence has shown that the rate of colonoscopy screening is increasing

concurrent with a decline in the uptake of other screening tests. In the 2005 National
Health Interview Survey (NHIS) study, the colonoscopy take up rate exceeded FOBT and
sigmoidoscopy (Meissner et al 2006). This study also concluded that a large proportion of
the take-up rate increment since 2000 was due to the increase in colonoscopy. The
American College of Gastroenterology (2000) recommendation that colonoscopy was the
preferred colorectal cancer screening test for average-risk individuals could have been the
reason for the large increase in colonoscopy rate (Rex 2000).
Colonoscopy, which requires sedation and often involves the use of a hospital or
surgery center suite, is more expensive than other screening tests and has a higher risk of
sedation and procedural complications (USPSTF (Baltimore 1996)). Retrospective
studies have reported the effectiveness of colonoscopy is superior to sigmoidoscopy
because approximately 60% to 70% of proximal cancers are not accompanied by
neoplasms in the distal colon, which is the examination zone of sigmiodoscopy (Dinning
1994, Castiglione 1995, Lemmel 1996). Therefore a large proportion of test-negatives
with sigmoidoscopy are not CRC-free. Proximal cancers account for 40% of the colon
cancers. These cancers remain undetected despite preventive screening using
sigmoidoscopy.
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Research has shown that individuals with any distal adenomatous polyps were
more likely to have advanced proximal neoplasia, the risk of advanced proximal
neoplasia is significantly enhanced by increasing severity of distal adenomatous polyps
(compared to patients without distal polyps). The relative risk of harboring distal
hyperplastic polyps, distal tubular adenomas, and advanced distal polyps were 2.6, 4.0,
and 6.7, respectively. Colonoscopy is irreplaceable among individuals without any distal
adenomas, because 2.7% had advanced proximal neoplasias (Lieberman 2000; Imperial
2000).
The effectiveness of colonoscopy in reducing CRC incidence and mortality
depends on how thoroughly visualization of the entire colon is achieved, the diligence in
examining the mucosa, and patient acceptance of the procedure (Denis et al 2011).
Colonoscopy has an advantage over barium enemas because it can be both diagnostic and
therapeutic. Its advantage over flexible sigmoidoscopy is that it can access the entire
colon while flexible sigmoidoscopy can only access the distal colon (Robertson et al
2006). The use of colonoscopy in colorectal cancer screening has increased concurrent
with the decline in barium enema and flexible sigmoidoscopy (Robertson 2006; Klbunde
2005).
In conclusion, FOBT serves as the most cost-effective in screening methods.
Barium enema, although cheaper than colonoscopy, is not useful for therapeutic purpose.
Sigmoidoscopy has similar features and is cheaper than colonoscopy. However, there is
ample documentation of missed suspicious lesions beyond the examination range of
sigmoidoscopy. Colonoscopy represents the most effective choice of screening method
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because it enables both detection and removal of suspicious lesions in on step. Even with
the price issue, screening with every 10 years makes it an attractive screening tool.
2.7 Quality of colonoscopy / effectiveness
Colonoscopy is currently regarded as the gold standard of colorectal cancer
screening by removing polyps/adenomas (colonoscopic polypectomy) because there is
strong evidence that polyps/adenomas are the precursor of colorectal cancer (Enterline et
al 1967, Grinnell et al 1958, Kalus et al 1972, Muto et al, 1975). The effectiveness of
colonoscopy screening in preventing the development of colorectal cancer depends on the
quality of examination. A successful colonoscopy can be identified by the rate of
polyps/adenomas detected and the cecum intubated by the performer’s series of
procedures. Achieving 95% cecal intubation rate is a recommended benchmark
(USPSTF). Missed polyp/adenoma rates are documented at 6% to 27% depending on the
size of polyps/adenomas (Hixson et al 1990, Rex et al 1997, Leaper et al 2004). Evidence
regarding the effectiveness of colonoscopy has caused other screening methods to
decline, and resulted in it being considered as the preferred method of CRC screening
(Rex 2000, Rex 2009, Davila 2006, NCCN Clinical practice guidelines in oncology
2011).
With increasing use of colonoscopy, measuring colonoscopy quality is becoming
inevitable to ensure its competent performance. Generally, the cecal intubation rate is the
most commonly studied quality indicator, but is a very inadequate indicator. Poor quality
colonoscopies limit its CRC protection potential.
Adenoma detection, which has a documented association with CRC prevention
and is the main goal of colonoscopy, should be a key indicator for studying colonoscopy
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quality. A wide range of ADR among endoscopists has been documented (Millan 2008,
Barclay 2006, Wilkins 2009, Rex 2001). This implies that the quality of colonoscopies
varies widely, which could severely undermine its efficacy in CRC protection. Another
major issue is the specialist capacity to meet the demand for colonoscopy screening if it
becomes the primary screening method. Some studies have explored the effectiveness of
colonoscopies performed by trained PCPs.
A meta-analysis of 12 eligible studies of colonoscopies performed by PCPs with a
total of 18,292 patients reported an adenoma detection rate of 28.9%. The authors
concluded that the performance of PCPs can meet the professional Societies’
recommended standards (Wilkins 2009). The association between colonoscope
withdrawal time and adenoma detection rate was also studied, Barclay (2006) indicated
that physicians who had a mean withdrawal time of less than 6 minutes (among patients
with no polyp removed) had an overall adenoma detection rate of 11.8%, while it was
28.3% for physicians whose mean withdrawal time was more than 6 minutes (without a
polyp found). This statistically significant difference persists in the mean number of
adenomas detected per subject, which were 0.17 vs. 0.61, respectively.
Rex et al (2001) videotaped 10 procedures performed by 2 colonoscopists and got
them reviewed/scored by 4 experts based on four quality criteria related to colonoscopic
withdrawal technique. They reported that technique does matter to the adenoma miss rate,
which could be further associated with the potential cancer protection efficacy of
colonoscopy screening. Winawer et al (1993) conducted a prospective clinical trial of
colonoscopy effectiveness (the National Polyp Study) over a mean follow-up of 5.92
years, documented a CRC prevention rate of 76% following colonoscopic adenectomy. A
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retrospective cohort study under an academic medical center setting reported a 100% of
CRC protection over a mean follow-up of 5.34 years (Imperiale et al 2008). Zauber et al
(2012) reported a 53% reduction in CRC mortality over a mean follow-up of 15.8 years
per subject.
Owing to its potential of a high level of CRC prevention, high-quality
colonoscopy is recommended to be performed every 10 years for average risk population
beginning at the age of 50 years, and 45 years for Blacks (Rex 2009). Colonoscopy every
5 years at the age of 40 years, or 10 years before the earliest age of CRC diagnosis in a
first-degree relative (high risk population) is recommended.
2.7.1

Procedure quality indicators
The National Comprehensive Cancer Network (NCCN) guidelines for CRC

screening indicate that to evaluate the quality of colonoscopy, the following indicators
should be considered (NCCN 2011):
•

Cecal intubation rate

•

Withdrawal time

•

Adenoma detection rate

•

Appropriate intervals between endoscopic examinations based on family and
personal history, and the number and histological type of polyps at last
colonoscopy

•

Minor and major complication rates

•

Pre-procedure medical evaluations

•

Appropriate bowel preparation instructions
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The cecal intubation rate and withdrawal time can be signal indicators for the
quality of colonoscopy screening. Cecum intubation is set as the standard for a completed
colonoscopy since the cecum is considered as the beginning of the large bowel. Reaching
the cecum implies that the colonoscope was inserted all the way through the colon and
rectum starting from the anus. In addition, withdrawal time (an average of 6 minutes or
more when no polyps are removed) can be the surrogate for the percentage of colonic
mucosa inspected (Barclay et al 2006, Rex 2006).
i.

Cecal intubation rate
Three types of cecal intubation rates are defined, the unadjusted rate, the MSTF-

adjusted rate, and the circumstance-adjusted rate. The unadjusted rate measures the cecal
intubation status for all study-eligible screenings. The MSTF-adjusted rate, according to
the MSTF recommendations is calculated by excluding incomplete colonoscopies due to
severe colitis or poor preparation (Rex 2002). The circumstance-adjusted rate further
excludes procedures in which the endoscopist made a clinical decision not to attempt to
reach the cecum because of severe diverticulosis, vital sign instability during the
procedure, obstruction or stricture, or because it was a therapeutic procedure without the
goal of cecal intubation, such as colon decompression, treatment of active lower
gastrointestinal bleeding, removal of a previously discovered lesion, stent placement,
etcetera (Aslinia 2006). The cecal intubation rate is the most commonly measured
indicator and relatively easy to report as a preliminary quality indicator of colonoscopy
(Aslinia 2006, Rex 2006, Rex 2002, Lieberman 2007).
ii.

Procedure time
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Colonoscope insertion time and withdrawal time are considered as appropriate
quality indicators (Lieberman 2007, Rex 2009), especially when the ADR is low (Rex
2006). Longer withdrawal time is shown to be associated with a better polyp detection
rate (Rex 2000, Sanchez et al 2004). In contrast, shorter withdrawal time periods were
associated with higher polyp miss rates (Rex 2000, Sanchez et al 2004). Also, the
insertion time, which is the examination time period from insertion to the anus to the
visualization of cecum, is documented to be associated with the adenoma detection rate
(Benson et al 2005). In a series of 550 average-risk consecutive colonoscopy screenings
performed by academic gastroenterologists, the ratio of insertion time to withdrawal time
was found to be positively related to the adenoma detection rate (Benson et al 2005).
2.7.2
i.

Outcome indicators
Polyps
A polyp is an overgrow tissue with part of its body attached to the site of origin.

Studies suggest that about 1 in 4 colon cancers develop from polyps (Morson 1974, Muto
et al 1975,Jass 1989), it takes averagely 10-15 years from a polyp to become a cancer by
progression through the Stages of an adenoma (Morson 1974). Identifying and removing
polyps during the screening exam has been considered the key to reduce the risk of
developing colon cancers (Pabby 2005, Rex 2002, Rex 2006). When there are multiple
polyps detected, they are most likely to be found in the ascending and transverse colon
(Correa et al 1977).
ii.

Adenomas
The adenoma detection rate has lately attracted attention as a key quality indicator

because the main goal of colonoscopy is to search for and remove all adenomas to
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prevent the CRC (Rex 2006, Lieberman 2007, Rex 2009). A positive correlation is
documented between withdrawal time and adenoma detection rate (Barclay 2006,
Barclay 2008, Millan 2008). Barclay et al (2006) study reported wide variation in the
mean number of adenomas per subject, in the adenoma detection rate, and in the mean
withdrawal time. With a mean withdrawal time more than 6 minutes, the physician’s
detection rates of adenoma in their patient panels are higher than physicians with less
than 6 minutes by around two and half folds (11.8% vs. 28.3%). The mean number of
adenomas detected per subject for physicians with a mean withdrawal time more than 6
minutes are nearly 4-fold larger than physicians with less than 6 minutes (0.17 vs. 0.61).
In another study Barclay et al (2008) studied the association of a minimum of 8 minutes
withdrawal time (mean for the endoscopist), and found that compared with endoscopists
with a mean withdrawal time less than 8 minutes, those with at least 8 minutes have
significantly higher rates of any neoplasia (37.8% vs 23.3%) and advanced neoplasms
(6.6% vs 4.5%). More importantly, among the advanced neoplasms found by those with
at least 8 minutes withdrawal time, 25% were 9 mm or less while for those with less than
8 minutes, only 10% were 9 mm or less. This indicates that the more gradual inspection
is, a higher number of smaller, potentially deadly neoplasms are found, some of which
are missed otherwise.
The adenoma detection rate shows a negative association with the risk of interval
cancer. With a higher adenoma detection rate at colonoscopy, the hazard ratio of interval
cancer for those physicians’ patients was reduced (Kaminski 2010). Compared with
physicians having an ADR of more than 20%, the hazard ratio of interval cancer for
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physicians with ADR less than 11% is 12.50, and about 11 for ADRs 11%-14.9% and
15.0–19.9% (Kaminski 2010).
2.8 Factors associated with CRC screening rates and adenoma rates
2.8.1

Patient factors
The factors associated with the uptake of CRC screening tests are widely

documented, and are similar to other prevention screenings, including race/ethnicity, age,
education, income, having health insurance coverage, and having a usual source of care.
One study evaluated the 1987, 1992, 1998, 2000, and 2003 National Health Interview
Survey (NHIS) findings (Meissner 2006). Use of CRC screenings was higher among
individuals with private health insurance, a usual source of care, and who were older,
White, married, having higher annual household income, and higher education (Meissner
2006). The prevalence of adenomatous polyps was positively associated with age, but
increasing age was not associated with an increase in polyp size (Rickert et al 1979,
Hughes 1968). The incidence of colorectal cancer is higher in males than in females
(Globocan (IARC) 2008, Jemal 2011, Meissner et al 2006). Nationally, the CRC
incidence for Blacks is 12.3% higher than Whites (Rex et al 2004). In South Carolina, the
disparity is worse; Blacks have approximately 30% higher incidence rates than Whites
(Daguise et al 2006). Overall, men have a higher screening take up rate than women
(Green et al 1999, Brawarsky et al 2003, Etzioni et al 2004). In 2000, women had a
greater use of FOBT than men, but men had a higher endoscopy rate than women (Seeff
et al 2004). Men had a higher uptake rate of sigmoidoscopy than women (Meissner et al
2006).

46

The CRC death rate remains highest among Blacks (Gargiullo et al 2002). This
may due to lower screening rates in this group (Thornton et al 2007; Zimmerman et all
2006; James et al 2006; Vlahor et al 2005; Shokar et al 2007; Shokar et al 2008; Zhao et
al 2006). At a population-level, reduction in CRC incidence rates are about 50% less
among Blacks than among Whites (Gargiullo et al 2002). CRC incidence rates among
Whites have been decreasing since 1985, and Blacks rates have remained relatively
unchanged (Gargiulo et al 2002; Jemal et al 2005; Ries et al 2000). Further, Blacks are at
higher risk of being diagnosed at an advanced or metastatic stage, where Whites are more
likely to be diagnosed at a non-advanced or localized stage (Weir et al 2003; Daguise et
al 2006).
Studies have demonstrated that Blacks suffered a higher proportion of adenomas
in the proximal colon than Whites, which in other words, more proximal adenomas in
Blacks that are missed by sigmoidoscopies (Thornton 2007, Johnson 1986, Ozick 1995,
Mayberry 1995, Nelson 1997, Thomas 1992, Rex 2000). What makes worse is Blacks are
documented to be less frequently screened by colonoscopy but sigmoidoscopy (Peterson
2008).
2.8.2

Physician factors in screening coverage
Although the effectiveness of colonoscopy screening in preventing CRC is

documented, screening colonoscopy coverage in the US population remains low. This is
partly due to the low endoscopy capacity due to a shortage of providers. Currently,
gastroenterologists are the main type of physician who performs screening colonoscopies.
The capacity for screening colonoscopies by gastroenterologists shows a big gap between
the supply of colonoscopies and the eligible population that needs to be screened.
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According to the American Board of Internal Medicine, there are only 13,968 certified
gastroenterologists in the US, annually increasing by460 gastroenterologists (ABIM
2013). The colonoscopy capacity is only 63% (14.2 millions) of the estimated annual
22.4 million colonoscopies (Seeff 2004), and the increase of the aging population,
including baby boomers, widens the gap. To cover 100% of all age-eligible
colonoscopies, an estimated additional 7,340 gastroenterologists are needed (Vijan 2004).
In South Carolina, an estimated 484,000 colonoscopies are needed annually to screen the
average-risk population older than 50 years; however, the current colonoscopy capacity
that could be provided if needed is 157,000, which shows an unmet need of two-thirds of
screening colonoscopies, which stands in the way of realizing the CRC prevention
benefits of colonoscopies (Seeff 2006). Similarly in Tennessee, the current estimated
colonoscopy capacity based on gastroenterologists’ numbers alone is for 84,000 nonMedicare insured patients per year to be provided screenings, whereas an estimated
950,000 to 1.1 million additional screening colonoscopies are needed (Cattau 2010). An
important point to consider is that when the supply of gastroenterologists is limited,
especially in rural areas, colonoscopies provided by trained PCPs could be a solution to
fill the gap. However, the widespread belief is that because gastroenterologists are
specialists, they will have superior performance than non-gastroenterologists. One study
showed that non-gastroenterologists detected colorectal cancer in 87% of patients with a
true cancer compared to 97.3% of true cancer detected by gastroenterologists (Rex 1997).
However, the distribution of incomplete colonoscopies among these groups was not
reported, which may influence the interpretation of outcomes. Another factor noted by
the author affecting the difference in cancer detection sensitivity of gastroenterologists
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compared with non-gastroenterologists was the lack of information in the latters’ training
in colonoscopy. Some of them were self-trained and others had variable (not
documented) levels of colonoscopy training.
Two Canadian studies reported that persons with colonoscopies performed by
non-gastroenterologists had a higher risk of subsequent CRC compared to those
performed by gastroenterologists. One retrospective cohort study of colonoscopies
conducted in Canada during 1992-1997 with up to a 15-year follow-up of 110,000
patients reported higher risks of interval cancer after a negative colonoscopy when
patients were provided the service in a hospital setting by non-gastroenterologists
compared to gastroenterologists (40% higher for general surgeons and 30% higher for
internists and family physicians), but no difference was found in physician office settings
(Rabeneck 2010). Another study matched colonoscopies done in 1997-2002 with the
Ontario Cancer Registry and also showed higher odds of CRC for non-gastroenterologists
compared with gastroenterologists among both men (OR=1.77) and women (OR=1.85)
(Bressler 2007).
In contrast, other research has shown that trained PCPs’ performance is
comparable or better than the current benchmarks of quality set by the US MultiSociety
Task Force (USMSTF) for gastroenterologists, from both the patient safety and adenoma
detection perspectives (Wilkins 2009, Xirasagar 2009). Pierzchajlo (1997) reported a
91.5% cecal intubation rate and 17.8% ADR among 751 colonoscopies performed by
family physicians, which meets the USMSTF recommendation that ≥90% of
colonoscopies should achieve cecal intubation consistently. This study’s ADR
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approaches the ADR standards of ≥15% for women and ≥25% for men (Rex, Bond,
Winawer 2002).
Another series of 200 colonoscopies performed by family physicians documented
highly competent performance by trained family physicians with 96.5% cecal intubation
rate and 22.5% neoplastic polyp detection rate (Edwards 2004). A retrospective case
review of 731 colonoscopies performed by two family physicians credentialed for
sigmoidoscopy and initially supervised by their referral gastroenterologist reported that
they had a ADR of 27.2% in men and 21.4% in women, though the cecal intubation rate
was close but lower than the USMSTF standard (89.5%) in their starting phase (19961998) and improved to meet the USMSTF standard (94.6%) at a later phase (1999-2001)
(Newman 2005).
Another potential reason to consider PCPs for screening colonoscopies is that
racially concordant PCPs may be more acceptable to black patients due to historic race
relations and trust issues. Black patients have a higher incidence of CRC (about 16%) and
47% higher CRC mortality than white patients. The age of CRC onset is earlier among
black patients, and CRC is more aggressive among younger age groups. Therefore it is
important to increase screening colonoscopy rates among black patients. A previous
study on the black PCPs trained in colonoscopy screening showed that they have a
significantly positive impact on their black patients’ colonoscopy screening rates, 66%
higher than those untrained in colonoscopy screening (9.4% before starting training vs.
48.3% after the PCP started doing procedures). For black patients of trained PCPs, they
are 5 times more likely to get a colonoscopy than white patients in the post training
period; during the same period, their white patients’ colonoscopy screening rates remain
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unchanged. In comparison, black patients of black untrained PCPs showed a change over
the same period from 10.4% to 38.7%, and the white patients from13.3% to 13.2%
(Xirasagar 2011).
Comparing estimates of the number of gastroenterologists needed with the newly
qualifying gastroenterologists each year, it will take approximately fifteen years to fill the
colonoscopy capacity gap (Vijan 2004, ABIM 2013). Having primary care physicians
perform screening colonoscopies may be a solution to cover the unscreened population,
which is 60% of currently eligible population (Seeff 2004). However, the training of
primary care physicians in colonoscopy remains very low. Only 4% of graduating family
medicine residents applied for colonoscopy credentialing in 2002 even though about half
of the residency programs offered colonoscopy training to family medicine residents, and
only 18% of these programs had anyone registering and getting trained (Wilkins 2004).
While research has documented that “trained” primary care physicians can provide
competent and safe colonoscopy (Edwards 2004, Newman 2005, Wilkins 2009), there is
no documentation of the training process or of the protocols used by high-performing
PCPs. This study presents the protocol that was consistently used to train primary care
physicians, which requires a 2-person technique, and includes other elements to
maximize colon surface inspection and to minimize the likelihood of missing polyps.
2.8.3

Procedure protocol features in colonoscopy quality – 2-person technique
Physician fatigue is reported to be a likely factor in adenoma detection rates,

particularly as the day progresses. Physicians’ ADRs for afternoon procedures were
significantly lower than those of their own morning procedures (25.3% vs. 29.3%,
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p=.008), with a 20% higher chance of detecting an adenoma in morning procedures
relative to afternoon procedures (Sanaka 2009).
The phenomenon of potentially lower quality output due to fatigue is not limited
to physicians. A study of the judicial system on the association between the likelihood of
favorable parole ruling in the morning compared with the afternoon showed that judges
were more likely to issue a favorable parole ruling in the morning than in the afternoon
and immediately after the lunch break than in the later afternoons. The authors suggested
that mental fatigue level may be less at the beginning of the work day and after a short
break to eat a meal or rest (Danziger 2011). In the case of colonoscopies, studies on the
presence of second observers in colonoscopy procedures are shown to increase the
colonoscopy quality in terms of adenomatous polyp detection. A retrospective study of
the involvement of an attending gastroenterologist and a gastroenterology (GI) fellow
reported that those procedures have significantly better ADR (37% vs. 23%, p<.01).
Similarly the mean number of adenomas detected per subject (MNA) was higher (0.56
vs. 0.3, p<.05), and the total number of adenomas detected among patients with
adenomas was higher (procedures with 2 adenomas found was 13.1% vs. 5.6%, P<.05; 3
and more adenomas found: 6% vs. 1.6%, p<.05) (Rogart 2008). These procedures had the
trained GI fellow performing the procedure while the attending gastroenterologist was
present in the room throughout watching the video screen and physically took over the
scope for the difficult or complicated situations encountered, letting the fellow complete
the remaining procedure after assistance was no longer needed. The procedure itself was
performed by one person (either the fellow or the attending gastroenterologist) at any
given point. Another retrospective study that was not limited to screening colonoscopies
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reported that the rate of small (<5mm) adenoma detection was significantly higher when
a fellow performed the procedure and the attending gastroenterologist observed the
screen, compared to the attending gastroenterologist performing the procedure without a
GI fellow present (25%vs. 17%, p=.001) (Buchner 2011). The authors specified that more
experienced fellows (e.g., the second-year and third-year fellows) can perform the entire
procedure with attending physicians’ oversight.
A reduced likelihood of missing lesions due to visual fatigue is one advantage of
having a 2-person technique where an additional person watches the video screen. In a
recent prospective study, having a dedicated endoscopy nurse observe the screen while
the attending physician performed the colonoscopy significantly increased the number of
polyps detected per patient (adjusted OR=1.26) compared to the attending physician
performing without a nurse observer. This effect was sustained for non-pedunculated
polyps, showing that the nurse observer contributed to the detection of flat/sessile polyps
(Aslanian 2013).
Improvement in adenoma detection with a second participant in the procedure is
further influenced by the experience level of the performer. Peters et al (2010) studied a
similar protocol where fellows performed screening colonoscopies under the supervision
of the attending physician. They compared these procedures with the GI attending
physician performing alone. Similar to other studies, they reported that with a second
practitioner involved in the procedure, tadenoma detection improved (odds ratio (OR)
=1.32). Further, this improvement was correlated with the fellowship year of the GI
fellow, the rate of adenoma detection for third-year fellows being almost double that of
first year fellows (OR =1.7). In a prospective study in Korea, six hospitals followed a
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protocol of having an endoscopy nurse administering the sedation under the
endoscopist’s supervision and also serving as a second observer of the video screen for
the colon inspection. As an observer, the endoscopy nurse assisted in identifying
suspicious lesions through the screen, with no hands-on assistance involved. With an
endoscopy nurse as a second observer, the likelihood of finding a polyp/adenoma
increased (OR =1.58 for polyp, and 1.47 for adenoma), an effect that was confined to
fellows performing their 150th-500th procedures (OR =2.07) and this effect was not
observed for senior attending gastroenterologists (Lee 2011).
However, another non-randomized prospective study conducted at a single-center
reported no significant difference in polyp detection rates with additional observers
(single-person: 32%, dual-observers: 33%) and in adenoma detection (19.3% vs 14.9%)
(Eckardt 2009). This study shared similar design elements as other studies: the trainee
performs the procedure while the attending physician supervises and provides rescue
assistance. The dual-person procedures showed a similar PDR as the single person
procedures, but showed a lower ADR because a higher proportion of diminutive (<5 mm)
hyperplastic polyps were removed in the dual-person groups.
To our knowledge, research on the “2-pearson technique” thus far has studied
similar protocols, namely, having a second person as “observer”. In our study setting, the
protocol uses a hands-on 2-person technique to compensate for the lack of specialist
training of the PCPs. In this protocol, a trained endoscopy technician advances the
colonoscope, and the PCP works the tip of the scope for polyp search and removal. This
method has the additional advantage of avoiding missing polyps due to physician's motor
fatigue particularly of the left or non-dominant hand. It confers the dexterity of two
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“right” hands (of the two participants) for polyp search and removal, and further, ensures
more persons watching the video screen for polyps. Additionally prior research on the 2person technique protocols involved a second observer with the polyp search limited to
the phase of withdrawing the scope. Our study center requires gradual insertion and
withdrawal of the colonoscope with polyp search and removal both during insertion and
withdrawal to maximize coverage of all mucosal surfaces and to minimize chances of
“losing” a polyp that may be encountered during insertion but not traced during the
withdrawal phase, which is the phase when gastroenterologists typically perform
polypectomy. Because of these differences, the 2-person technique protocol in our study
setting is unique and when applied to PCPs, the question arises, does this technique
enable the quality of PCP-performed colonoscopies to be comparable to specialistperformed colonoscopies. This study addresses this research question.
2.8.4

Sedation during colonoscopy
Colonoscopy can be painful and stressful to patients. The fear of discomfort may

prevent some persons from accepting CRC screening. Concerns regarding unsedated
colonoscopy may provide a negative perception of colonoscopy to the public, and hence,
diminish the acceptability of colonoscopy, impeding the early detection of adenomatous
lesions and thereby, limiting CRC protection (Rex & Khalfan 2005, Sipe, Rex ,
Latinovich 2002). Pain control is a priority for patients. Deep sedation puts patients into
an unconscious state during the procedure and relieves patients of the anxiety of the
impending discomfort. Deep sedation is therefore recommended, based on evidence that
patients experienced little/no pain and that the endoscope is more readily advanced
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through the colon when the patient is deeply sedated (Rex & Khalfan 2005, Sipe, Rex,
Latinovich 2002, Heuss 2004).
Sedation for routine colonoscopy is either moderate or deep. Moderate sedation
induces a state of drowsiness or sleep during most of the procedure, and is commonly
performed with a benzodiazepine alone or with narcotics/opioids. Patients with moderate
sedation can be readily awakened when spoken to or touched (American Society of
Anesthesiologists (ASA). Deep sedation is a state where patients are asleep throughout
the procedure with little or no memory, commonly induced with propofol. Patients with
deep sedation breathe slowly, requiring oxygen at times, and sleep deeply until the
medication wears off (ASA).
Physical status is evaluated before sedating patients to assess fitness for the
procedures as per the ASA Physical Status Classification System (Source: The Cleveland
Clinic Foundation). This was developed in 1963 and is conventionally used:


ASA PS1: the normal healthy patient (no organic, physiologic, or psychiatric
disturbance; excludes the very young and very old; healthy with good exercise
tolerance)



ASA PS2: patients with mild systemic disease (no functional limitations; has
well-controlled disease of one body system; controlled hypertension or
diabetes without systemic effects, cigarette smoking without chronic
obstructive pulmonary disease (COPD); mild obesity, pregnancy)



ASA PS3: patients with severe systemic disease (some functional limitations;
has a controlled disease of more than one body system or one major system; no
immediate danger of death; controlled congestive heart failure (CHF), stable
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angina, old heart attack, poorly controlled hypertension, morbid obesity,
chronic renal failure; bronchospastic disease with intermittent symptoms)


ASA PS4: patients with severe systemic disease that is a constant threat to life
(has at least one severe disease that is poorly controlled or at the end-stage;
possible risk of death; unstable angina, symptomatic COPD, symptomatic
CHF, hepatorenal failure)



ASA PS5: moribund patients who are not expected to survive without the
operation (not expected to survive > 24 hours without surgery; imminent risk
of death; multiorgan failure, sepsis syndrome with hemodynamic instability,
hypothermia, poorly controlled coagulopathy)



ASA PS6: a declared brain-dead patient whose organs can be removed for
donation purposes
The efficacy of sedation is often assessed by the observer’s assessment of the

patient on the alertness/sedation scale (Table 2-3) (Chernick 1990):
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Table 2-3 the observer’s assessment of the patient on the alertness/sedation scale
Composite Responsiveness
Speech
Facial
Eyes
score
Expression
Responds readily to
Normal
Normal
Clear, no
5
name spoken in
ptosis
normal tone
Lethargic response to Mild slowing
Mild relaxation Glazed or mild
4
name spoken in
or thickening
ptosis (<1/2
normal tone
eye)
Responds only after
Slurring or
Marked
Glazed and
3
name is called loudly prominent
relaxation
marked ptosis
or repeatedly
slowing
(slack jaw)
(>1/2 eye)
Responds only after
Few recognized /
/
2
mild
words
prodding/shaking
Does not respond to
/
/
/
1
mild
prodding/shaking
Source: Chernick DA, Gillings D, Laine H et al. Validity and reliability of the observer’s
assessment of alertness/sedation scale: study with intravenous midazolam. J Clin
Psychopharmacol 1990; 10: 244-51.

2.8.5

Sedation type and colonoscopy quality
There is little documentation of associations between sedation type and

colonoscopy procedure quality and outcomes. The available evidence is mixed. Two
major quality indicators, the procedure completion rate (cecal intubation), and adenoma
detection rate show positive associations with deeper sedation in some studies (Chelazzi
2009, Radaelli 2008, Wang 2010), and show no significant associations in other studies
(Paspatis 2011, Rex 2012, Metwally 2011, Bannert 2012).
Chelazzi et al (2009) reported that procedures carried out under propofol sedation
have a 100% completion rate, while non-sedated procedures had only 91.1% completion
rate (p<.05). The median insertion time was 9 minutes for the propofol group and 10.5
minutes for the non-sedated group (p=.0086). In the same study, the total procedure time
mirrored the insertion time pattern (15 min. vs. 19.5 min., p=.09). Because bowel
preparation status significantly influences cecum intubation, Radaelli et al (2008) studied
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the association between contribution of bowel preparation status, and sedation type.
When compared to excellent bowel preparation, good bowel preparation is around 40%
less likely to intubate the cecal (OR =0.586; poor: 0.246, inadequate: 0.013). Regarding
sedation type, propofol-sedated procedures had the highest odds of cecal intubation (OR
=2.355), followed by the benzodiazepines and opiate regimen (OR =2.128), followed by
the benzodiazepines alone (OR =1.46), compared to the no sedation group (OR =1). This
study also explored the associations with polyp detection, and reported similar direction
of associations to cecal intubation. The likelihood of detecting any polyp was highest in
the propofol group (OR =1.317) compared to the non-sedated group, followed by
benzodiazepines alone (OR =1.121), and there was no significant difference between no
sedation and the benzodiazepines and opiate group (OR=1.105, p>.05).
A study from Greece using midazolam and pethidine sedation for all procedures,
distinguished between moderate sedation (MS) and deep sedation (DS) based on dosage.
They reported no significant difference in polyp detection rates (MS: 61.5%, DS: 63.6%),
adenoma detection rates (MS: 59.5%, DS: 60.4%), and right colon polyp detection rates
(MS: 34.4%, DS: 36.8%) (Paspatis 2011). Another study showed no difference between
procedures sedated by propofol and by midazolam/fentanyl in adenoma detection rates
(OR=1.07 (95%CI: 0.91, 1.26 for propofol)) (Metwally 2011). A retrospective cohort
study across 72 facilities reported that with moderate sedation, the polyp detection rate
was higher than deep sedation (37.7% vs. 34.1%, p<.0001). However, the advanced
adenoma rate was higher for deep sedation (7.2% vs. 6%, p=.01), the effect being greater
in facilities where deep sedation procedures exceeded 10% of its total procedures (7.5%
vs. 5.7%, p=.003) (Wang 2010).
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While evidence for procedure completion and detection of adenomatous polyps is
mixed, sedation use has shown higher patient satisfaction on pain control. Propofol
sedated patients were the most consistent in reporting no pain (102 out of 102 patients),
while the midazolam group (17 out of 23 patients) and no sedation group (11 out of 22
patients) had very low percentages indicating no pain (Gasparovic 2003).
The duration over which the patient achieves adequate sedation (onset time) and
the duration in which the patient remains drowsy after the procedures (recovery time)
remain important. When compared with moderate sedation, the deeply sedated group
showed a shorter sedation onset time (time to sedate). Ulmer et al (2003) reported a mean
sedation time of 2.1 minutes for propofol and 6.1 minutes for midazolam/fentanyl
(p<.0001). For recovery time, studies have reported 7 to 16.5 minutes for propofol, 27.5
minutes for midazolam/ fentanyl, 20 minutes for midazolam alone, and 33 minutes for
midazolam/meperidine (Sipe 2002, Gasparovic 2003, Ulmer 2003). Deep sedation by
propofol is significantly time saving as both procedure time and recovery time are
shortened, compared to moderate sedation by any other sedative or combination of
sedatives. However, the mixed results for the other quality indicators suggest the need for
studies in settings where other protocol-related and procedure-related elements that
influence these quality indicators are fixed, enabling unambiguous determinations of the
sedative effect on these indications. A major limitation in comparing the various studies
in sedation type vs. adenoma rate is the wide (undocumented) variation in all the other
elements of the colonoscopy protocol and procedure times that would impact the ADR.
Our study setting compared patients sedated with propofol (all procedures starting from
April 2006) with midazolam-meperidine procedures pre-April 2006.
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2.9 Significance of the research
This research is based in a setting where all the remaining colonoscopy protocol
elements other than the two study items were fixed throughout the study period. This
allows the specific protocol elements (2-person technique or sedation type) to be
accurately evaluated for their impact on ADR and other metrics of colonoscopy quality.
An earlier study of 10,958 colonoscopies performed by 51 PCPs between October
2002 and November 2007 in this setting documented the high quality of screening
colonoscopies performed by PCPs, all of whom were required to use the 2-person
technique along with polyp-maximizing protocol. The quality indicators in that study
cohort exceeded the ASGE-recommended standards of quality. The cecal intubation rate
was 98.1%, which is higher than the ASGE standard of 95%. The adenoma detection rate
was 30%, 34.6% in men and 25.4% in women, which are both above the ASGE standard
(men ≥25%, women≥15%). The minimum withdrawal time recommended by the ASGE
when no polyps are found is 6 minutes compared to the mean withdrawal time of 8
minutes for no polyp procedures in a subset of the current study cohort (Xirasagar 2010).
Other research has also documented that trained PCPs’ performance quality can meet the
current benchmarks of quality established by the US MultiSociety Task Force on
colonoscopies for gastroenterologists on both patient safety indicators and adenoma
detection rates (Pierzchajlo 1997, Edwards 2004, Wilkins 2009, Newman 2005).
It is possible that racially concordant PCPs may be more acceptable to black
patients due to historic race relations and mistrust of black providers. A study of the
patient panels of these PCPs showed high colonoscopy completion rates of 48.3% among
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black patients of black PCPs trained in colonoscopy screening, showing a five-fold
increase compared to before training rates (Xirasagar 2011).
Literature regarding the relationship between propofol sedation and colonoscopy
quality has focused largely on shorter onsets of sedation and shorter recovery times (Sipe
2002, Gaspsarovic 2003, Ulmer 2003) and on better pain control (Gasparovic 2003) and
procedure completion (Chelazzi 2009, Radaelli 2008). The evidence regarding propofol
contribution to the detection of adenomatous polyps remains mixed, with no resolution in
sight due to a lack of standardized procedure protocols across procedures with potential
confounding.
In short, the associations of the study center’s innovative hands-on 2-person
technique with adenoma detection rates, and the associations of propofol sedation with
clinical quality indicators need rigorous study. Additional indicators such as likelihood of
finding smaller adenomas, and anatomic locations have not been studied so far. This
study will test hypotheses regarding the associations of 2 protocol elements, 1) 2-person
technique, and 2) propofol sedation, with adenoma detection rates, numbers of adenomas
detected, procedure times, polyp sizes and polyp locations. The purpose is to further
clarify whether these two protocol elements improve effectiveness in adenoma detection
and therefore, effectiveness in preventing further colorectal cancer.
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Chapter 3

METHODS

This chapter discusses the methodology used in this study. Sample selection and
statistical analysis methods used to achieve the study objectives will be displayed in this
chapter.
3.1 Research questions and Hypothesis
An earlier study documented the high quality of screening colonoscopies
performed by PCPs in this study setting without assessing the role of the 2-person
technique in the results (Xirasagar et al 2010). In that study a subset of the current series
showed a cecal intubation rate of 98.1% , an adenoma detection rate of 30% (34.6% in
men and 25.4% in women), and a mean colonoscope withdrawal time (when no polyps
were found) of 8 minutes. The quality indicators in this study cohort exceed the ASGErecommended standard (Xirasagar 2010). Studies regarding the 2-person technique have
been limited to having a second observer in the procedure room (Rogart 2008, Buchner
2011, Lee 2011). The 2-person technique element of the protocol in this study refers to
having an endoscopy technician provide “hands-on” assistance to the endoscopist
throughout the procedure in advancing and withdrawing the endoscope. In this study
setting, all 54 PCPs who performed colonoscopies were required to use the 2-person
technique. Among specialists/experts, 2 of them chose not to use the two-person
technique. We studied the quality indicators in these three groups of procedures.

63

The documented literature regarding propofol sedation has focused on sedation
onset and recovery time (Sipe 2002, Gasparovic 2003, Ulmer 2003), or better pain
control (Gasparovic 2003) and procedure completion (Chelazzi 2009, Radaelli 2008),
while the effect on detection of adenomatous polyps remains controversial.
This study will address the following research questions:
1) Is the quality of colonoscopy performance by PCPs using a hands-on 2-person
technique similar to that of specialists using a routine protocol (one person
technique)?
2) Within specialists, does the 2-person technique improve the adenoma yield and other
indicators of better adenoma clearance?
3) Does propofol sedation improve the quality of colonoscopy performance outcomes?
For all questions, we will study the indicators of adenoma detection rates, numbers
of adenomas detected, procedure times, polyp sizes particularly small adenoma
detections, and polyp anatomic locations.
3.1.1

Research questions
The literature and explanation documented in the previous chapters map out the

research questions:
1) Does the protocol element, 2-person technique, improve screening colonoscopy
quality in terms of the adenoma detection rate, the number of adenomas, the size of
polyp, and the location of polyp?
2) Is sedation type associated with performance quality in terms of the adenoma
detection rate, the number of adenomas, the size of polyp, and the location of polyp?
3) Is there an association between procedure time and 2-person technique?
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4) Is there an association between procedure time and sedation type?
3.1.2

Study hypotheses

1) Hypotheses related to the hands-on 2-person technique:
a) The likelihood of detecting a/an polyp/adenoma by PCPs using 2-person
technique and specialists using 2-person technique is higher than specialists using
1-person technique. (In this center, no PCP was permitted to perform with the
solo technique)
b) More polyps/adenomas are detected by 2-person technique PCPs and specialists
than solo-performing specialists.
c) More number of small polyps will be detected by 2-person technique PCPs and
specialists than that of solo performing specialists.
d) The likelihood of detecting a right colon polyp will be higher for 2-person
technique PCPs and specialists than solo-performing specialists.
2) Hypotheses related to sedation type:
a) Propofol sedation procedures are more likely to be associated with a/an
polyp/adenoma detected than Midazolam-meperidine sedation procedures, and the
increased likelihood will be observed for large and small polyps.
b) Propofol sedation procedures are more likely to be associated with detection of
right colon polyps than Midazolam-meperidine sedation procedures.
3) Hypotheses related to procedure duration:
a) Procedure time is longer with the 2-person technique than with 1-person
technique after controlling for number of polyps found.
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b) Procedure time is longer with the 2-person technique specialists than with 1person technique specialists after controlling for number of polyps found.
4) Hypothesis related to the fourth research question:
a) Propofol is associated with longer procedure time than Midazolam-meperidine as
patient will be well sedated and the endoscopist can take time to complete the
procedure carefully.
3.2 Methodology
3.2.1

Data source
The setting of this study is a state-licensed ambulatory surgery center for

endoscopy, South Carolina Medical Endoscopy Center (SCMEC), in Columbia, South
Carolina. To begin with, the Center trains PCPs with didactic instruction followed by a
colonoscopy simulation model, and then initiates clinical procedure training with
patients. The Center requires hands-on supervision and participation by the specialist for
the first 140 procedures (the ASGE-prescribed level for gastroenterology residents to be
credentialed for independent colonoscopy performance, Faigel 2007). The
specialist/expert (gastroenterologist/colorectal surgeon) initially provides the PCP with
hands-on assistance to push the scope and assist with tip manipulation and polypectomy
up to 140 procedures. The frequency of manual assistance by the expert/specialist is
gradually reduced, and transitioned to the verbal assistance to navigate difficult colonic
segments and/or diverticula. Finally, post-training the PCP performs without specialist
oversight, and the specialist intervention is limited to therapeutic assistance when called
upon to remove advanced adenomas, polyps at difficult locations, control bleeding,
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and/or manage spasms. The Study Center’s training of PCPs was started in 2001, and 54
PCPs were trained as of February 4, 2011.
The SCMEC protocol requires a 2-person technique for all PCPs regardless of
training status, i.e., even after training. All PCPs have to bring their patients to the
SCMEC and cannot perform the procedure at their own offices. The SCMEC innovative
protocol has the following unique features: a) (After training procedures are completed)
An endoscopy technician advances the colonoscope while the physician manipulates the
scope tip for polyp search and removal. This method minimizes the missing of polyps
due to physician's motor fatigue, confers the dexterity of two “right” hands for polyp
search and removal, and ensures more persons watching the video screen for polyps. b)
Since April 2006, propofol sedation occurs instead of the conventional midazolammeperidine combination sedation, c) Gradual insertion and withdrawal for polyp search
and removal maximizes the coverage of the colonic mucosal surface, d) A minimum of 3
persons watch the video-screen to identify abnormal mucosa and polyps to assist the
performing physician.
This is a retrospective study of all screening colonoscopies performed between
September 4, 2001, through February 4, 2011, at the SCMEC. Over the study period, 59
physicians performed the procedures included. The Center’s innovative protocol of 2person technique was consistently complied by 57 physicians (54 PCPs and 3 specialists),
PCPs are defined as those with family medicine, internal medicine, pediatrics or
obstetrics/gynecology specializations. Two specialists (one colorectal surgeon and one
general surgeon during one year) did not follow the 2-person technique.
3.2.2

Approaches to test the study hypotheses
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We first tested the effect of sedation type on 59 physicians performance in terms
of procedure time, cecum intubation, polyp and adenoma detection before (Midazolammeperidine sedation) and after the execution of propofol sedation at a procedure cut point
of April, 2006. Our hypothesis regarding the effect of the two-person technique features
of the new protocol is that specialists should perform better than PCPs within the twoperson technique procedures in terms of our quality indicators. To validate the
hypothesis, quality indicators were compared of two specialists who did not follow the
innovative protocol with three specialists who did, and PCPs (all 2-person technique).
The effect of the 2-person technique within specialists was also evaluated. Two
specialists not following the new protocol were compared with the remaining specialist
endoscopists who followed the protocol.
The hypothesis regarding sedation type is that patients sedated by propofol should
have better outcomes than those sedated by Midazolam-meperidine in terms of our
selected quality indicators. To validate the hypothesis, the quality indicators of patients
sedated by Midazolam-meperidine were compared with patients sedated by propofol.
The quality indicators of interest were procedure time, cecum intubation rate,
likelihood of polyp detection and adenoma detection, the number of polyps/adenomas
detected per screened person (MNP/MNA), polyp size, and detection of right-sided
polyps. MNP and MNA were to show the total polyps/adenomas each physician found
among their procedures calculated into a mean per screened person. The size of the polyp
is the diameter, categorized as ≦5mm, 6 – 9 mm, or 10+ mm. Polyp location refers to
anatomic location in the colon, left colon or right colon.
3.2.3

Regression Models
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In selecting the multivariate analysis method, we had to ensure that the statistical
analyses address non-independence of data due to clustering of patients within physician.
Random-effect regression models address such clustering by incorporating a random
effect for physicians and fixed effects for other covariates in the model. Alternatively,
fixed-effects regression models incorporate a fixed effect for each physician, though this
approach is more difficult to translate to data from other physicians. Finally, generalized
estimating equations (GEE) modeling, assumes a specific correlation structure for the
repeated measures data per physician. We modeled our data using GEE Models for
which we assumed an exchangeable correlation structure. This structure assumes that
any two observations from different physicians are uncorrelated, and any two
observations from the same physician are the same value (no matter which physician).
Our inference was based on statistics constructed from the modified sandwich variance
estimator so that inference is robust to any within-physician correlation structure no
matter how different from exchangeable. GEE was used because it accommodates withinphysician correlation without focusing attention on that aspect of the data analysis. The
within physician correlation is treated as an ancillary problem to be accounted for but not
of profound interest. When using the exchangeable correlation structure for a linear
model, the regression parameters of the GEE are algebraically equivalent to the
correlation among patients within a physician panel. The same is not quite true for
inference of regression parameters from the logistic GEE and logistic random effect
models. GEE was determined to be the optimum modeling tool for these analyses.
a. Testing the association of a protocol feature with procedure time
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GEE is used to model covariates in a generalized linear model with either
unknown or expected correlation between outcomes. It is described as follows:
“It is a method of analyzing correlated data that otherwise could be modeled as a
generalized linear model. GEEs have become an important strategy in the analysis of
correlated data. These data sets can arise from longitudinal studies, in which subjects
are measured at different points in time, or from clustering, in which measurements
are taken on subjects who share a common characteristic such as belonging to the
same litter.” (SAS online support)
Linear GEE regression was used to study the association between the procedure
time and our variables of interest. The hypotheses tested using this regression method
were as follows:
1) Patients subjected to the 2-person technique will have longer procedure times
than under the 1-person technique after controlling for the number of polyps found. (This
is because having an extra person hands-on serves to reinforce the Center’s requirement
of gradual insertion and withdrawal of the colonoscope to carefully work with the folds
and search for polyps covering all possible mucosal surfaces.)
2) Within the 2-person technique group, PCPs will have longer procedure times
than specialists after controlling for the number of polyps found. (This is expected
because PCPs may have less skill than specialists in navigating the colonoscope)
3) Propofol-sedated patients will have longer procedure times than midazolammeperidine-sedated patients after controlling for the number of polyps found. (This is
likely because of better pain control under propofol. Thus the need to rapidly wind down
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the procedure due to patient discomfort should be less common with propofol than with
Midazolam-meperidine.)
b. Testing the likelihood of finding any polyps/adenomas/advanced neoplasms
Logistic GEE regression, a regression model for dichotomous dependent variables,
was used to test the hypotheses regarding PDRs, ADRs, and advanced neoplasms
detection rates. Hypotheses tested by GEE were:
1) 2-person technique procedures will be more likely to have at least one
polyp/adenoma/advanced neoplasm detected than 1-person technique procedures,
2) Within the 2-person technique group, PCPs will be as likely as specialists to detect at
least one polyp/adenoma/advanced neoplasm,
3) Propofol sedated patients will be more likely to have at least one
polyp/adenoma/advanced neoplasm detected than the Midazolam-meperidine sedated
group.
c. Testing the likelihood of finding additional polyps and adenomas, and the
likelihood of finding progressively smaller polyps as well as the likelihood of
right colon polyps
Ordered logistic GEE regression, a regression modeling method for ordinal
dependent variables was used to test whether the likelihood of finding each additional
polyp/adenoma in a patient, the likelihood of finding progressively smaller polyps, and
the likelihood of finding a right colon polyp, increased with the use of the 2-person
technique.
Our study hypothesized that compared with the 1-person technique, 2-person
technique procedures are more likely to be associated with at least one polyp found

71

relative to zero polyps. This relationship remains the same when moving to the next
comparison level, i.e. finding 2 polys vs. only one polyp. Likewise, for the size of the
polyp, we hypothesize that compared to the 1-person technique, 2-person technique
procedures are more likely to be associated with a small (≦5 mm) polyp found relative to
a medium (6-9 mm) polyp. The relationship is hypothesized to be similar for the next
level of polyp size, that compared to the 1-person technique,2-person technique
procedures are more likely to be associated with a medium (6-9 mm) polyp found relative
to a large (10+mm) polyp. Finally, for polyp anatomic location, we hypothesize that
relative to the 1-person technique procedures, 2-person technique procedures are more
likely to be associated with at least one right colon polyp found relative to only left colon
polyps found.
Regarding sedation type, the assumptions is that compared to midazolammeperidine sedation, propofol-sedated procedures are more likely to be associated with at
least one polyp found relative to zero polyps. The same association carries to the next
level as explained above. As for polyp size, we hypothesize that compared to the
midazolam-meperidine sedation, propofol-sedated procedures are more likely to be
associated with detecting small (≦5 mm) polyp(s) relative to medium (6-9 mm) polyps.
The relationship remains the same on the next level, which means compared to the
midazolam-meperidine sedated group of procedures, the propofol sedated procedures are
more likely to be associated with finding a medium (6-9 mm) polyp found relative to
finding only a large (10+ mm) polyp. Lastly, compared to midazolam-meperidine
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sedation, propofol-sedated procedures are more likely to be associated with finding at
least one right colon polyp relative to only left colon polyps found.
3.3 Preparing and cleaning the data
3.3.1

Data extraction and sample data
A total of four datasets without personal identifying information on all

colonoscopies conducted during September 4, 2001 and February 4, 2011were extracted
into Microsoft EXCEL from the SCMEC computers into University of South Carolina
(USC) computers. The four datasets were physician dataset, procedure dataset, polyp
dataset, patient dataset (appointment and race gender information stored in Mysys and
FoxPro at SCMEC).
The physician dataset includes the information related to the physician, such as
the physician name, the gender, the race, age as of 2007, the year of graduation, the area
of specialty, and board certification. The procedure dataset includes the clinical
procedure notes: time of scope insert and time out of anus, the time of staring the
withdrawal (when cecal was viewed), was the sequential number of this procedure under
the training process, and the section of the colon up to which the colonoscope was
advanced to for the patient in this procedure, the procedure date, and was this procedure
performed by a specialist or a PCP etc.
The polyp dataset contains the histology of the polyp, was this polyp an adenoma,
the size of the polyp, the hyperplasia percentage/severity of the polyp, dysplasia level,
was the polyp removed, how was the polyp removed, and location of the polyp. The
patient dataset contains data on patient age as of the procedure date, gender, race, and
date of birth.
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3.3.2

Linking, clearing and acquiring missing data

All datasets were linked by the procedure identifier (ID). In addition to the procedure
ID, there is a patient ID linking multiple procedures for the same patient. In this study,
we used data on only the first screening colonoscopies of each patient (initial
colonoscopy).Over 10,000 patient charts were reviewed to fill in missing data and to
resolve typographical errors/discrepant information between the datasets. Updates were
carried out in the summer and fall 2011, and the summer and fall of 2012. Variables
corss-checked were patient date of birth, procedure date, bowel preparation status,
procedure time points (time of insertion, viewing cecum, and withdrawal), and all
variables of the polyp data to verify a polyp characteristics.
After merging the above datasets and missing data/discrepant data entered, duplicates
were removed, cancelled patient appointments were removed, procedures that were
performed by the SCMEC director at a neighboring hospital were removed, and variables
were renamed and labeled. Some variables were recoded/extracted from text fields, some
of the data categories were recoded, such as dysplasia level recode, which accommodated
information from two variable fields, pathologytext and path_results. In October 2012,
two rounds of manual review of text fields and recoding of polyp_results were done to
retrieve missing data for 4,746 polyps due to the mis-categorized information by SCMEC
staff in a different variable field in the polyp dataset. After cleaning the procedure and
polyp datasets, we summarized the polyp data by procedure and linked the summarized
polyp information to procedure dataset by procedure ID for studying indicators of
procedure performance.
3.4 Inclusion and exclusion criteria
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We selected only screening colonoscopies of average risk population consistent
with the objective of this study. Therefore, we first excluded the second and later
procedures for each patient. After extracting initial procedures, patients aged less than 30
years or older than 90 years were excluded because these age groups are not the target of
routine screening as per USPSTF screening guidelines. In addition to age exclusion, we
excluded patients with prior history of colon/rectum resection because they are no longer
in the average risk pool once they were diagnosed as colon/rectum related diseases.
3.5 Sample selection
Retrospective data on all 26,523 colonoscopy procedures performed from
September 4, 2001 to February 4, 2011 were evaluated for selection of screening
colonoscopies (the first colonoscopy of the patient). A total of 5,611 second and later
procedures were excluded. Of the 20,912 patients with an initial colonoscopy, we
excluded patients less than 30 years of age or older than 90 years (342 patients) and those
with prior history of colon/rectum resection (30 patients). Figure 3-1 shows the sample
selection flow chart with exclusions by the above criteria leading up to the study sample
of 20,540 consecutive colonoscopies conducted by 54 PCPs and 5 specialists during the
study period of September 4, 2001 through February 4, 2011.
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26,523 procedures
as of February 4,
5,611 2nd and later procedures
20,912 initial
342 <30 years & ≥90 years
20,570 patients with initial
colonoscopy 30-89 years
30 excludes dues to prior
history of colon/rectum
resection
20,540 study eligible

604 patients with 1person technique

15,203 patients
with 2-person

4,773 patients with 2person technique

Figure 3-1 Sample Selection Flowchart
3.6 Defining the key variables of interest
To identify patients with and without polyps, we summarized polyps by patientid
in polyp dataset. Below are list of our study variables:
•

Patient age

•

Patient race

•

Patient gender

•

Sedation type

•

Protocol type

•

Polyp

•

Adenoma
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•

Number of polyp found per subject

•

Number of adenoma found per subject

•

Procedure time

•

Bowel preparation

Quality indicators
The procedure time, named Timeproc is calculated from the original downloaded
fields from SCMEC – starttime and endtime. Time during the day was extracted as
starttime and endtime usng the raw variables ScopeIn and Scopeout. The interval in
seconds between ScopeIn and ScopeOut was taken and divided by 60 to calculate
TimeProc in minutes.
For polypsize, variable polypsizemm is used to categorize polyps into three
groups, “≤5mm”, “6-9mm”, and “10+mm”. For polyp location, PolypLocation was the
original variable used to create the intermediate variables. Polyp location was defined as
proximal if located in the cecum, ascending colon, hepatic flexure, and transverse colon,
and as distal if located in the splenic flexure, descending colon, sigmoid colon, or rectum.
For those located in the proximal, we coded as “right colon”, for the remaining, “left
colon” .
Adenoma and polyp detection rate
Adenoma detection is our key dependent variable to define the quality. To detect
adenomas (which are identified by pathologic examination of polyps), endoscopists must
first find the polyps during the colonoscopy, classify the polyp by gross appearance, and
take part of the lesion to lab for biopsy to confirm the histology of the polyp. Therefore,
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we first study the polyp detection and then proceed to adenoma detection as our key
variables of interest.
Polyp detection rate is defined as the percentage of patients with at least one
polyp found. Each polyp has a polypid and a procedureid to link to the patient it belongs
to. To identify the likelihood of a patient having a polyp, we summarized the polyps in
each patient into a polyp dataset. If a patient ID exists in the polyp summary dataset, the
patient was coded as “Yes” for the polyps variable in the procedure dataset, and if not, it
was coded“No”. To calculate the polyp detection rate, patients with polyps equal to
“Yes” are divided by total patients. Adenoma detection rate is calculated by the same
process.
For the number of polyps found per subject, polyps were summarized within each
patient using patient ID in the polyp dataset and the variable with count of polyps was
merged into procedure dataset as SumPolyps using the patientid. A similar process was
used for the number of adenomas found per subject, named SumAdenomas.
Protocol type
The protocol type was classified at the level of provider using the providerID
from SCMEC. Per SCMEC, providerID equal to 56 and 64 were classified as 1-person
technique specialists, whereas providerID equal to 1, 22 and 59 were classified as 2person technique specialists, and the remaining physicians were PCPs all using 2-person
technique. Procedures by these respective physicians were thus assigned to the protocol
category stated above.
Sedation type
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The sedation type is categorized by procedure date. Every procedure conducted
before April 1, 2006 was categorized as Midazolam-meperidine sedated procedure, while
April 1, 2006 and after were propofol-sedated procedure.
Control variables classified
Patient age was calculated from patient date of birth downloaded from the
SCMEC’s administrative billing system. The continuous variable of age was recoded into
four age groups: <50 years, 50-59 years, 60-69 years, and 70-89 years. Patient gender
was downloaded from the SCMEC’s administrative system coded as male and female.
Patient race is coded as Whites, Blacks, Other and unknown (missing information).
The bowel preparation status, bowelprep, is based on a field directly downloaded
from SCMEC data system called ColPrep. If ColPrep was equal to missing, it remains
missing in bowelprep. If ColPrep equal to “excellent”, it remains the same in bowelprep.
If ColPrep indicated “fair” or “good”, it was re-coded “fair” in bowelprep. If ColPrep
equal to “poor”, it remains the same in bowelprep.
The variable to classify training procedure or not, named training is based on a
field directly downloaded from SCMEC administrative system called ColPCPSeq. All
primary care physicians had their cumulative procedures assigned for each procedure
because their very first training procedures started at the study center. Specialists do not
qualify for procedure volume variable and have a missing value in this field because all
of the specialists completed their first 140 training procedures before getting credentialed
in colonoscopy during their training. Therefore, if ColPCPSeq equals to “missing” or
more than 140, training of this physician will be coded as “No (0)”. If ColPCPSeq less
than or equal to 140, training value is “Yes (1)”.
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Interaction terms to be tested
We further studied the interaction between bowel preparation status (excellent,
fair and poor) and sedation type. To test the effect of interaction six categories were
created based on bowelprep and sedation variables, which are Midazolammeperidine/Poor, Midazolam-meperidine/Fair, Midazolam-meperidine /Excellent,
Propofol/Poor, Propofol/Fair, Propofol/Excellent.
The cecal intubation rate, named cecalintub, is coded based on original fields
downloaded from SCMEC – termileumintubated and advnacedupto. If
termileumintubated equal to “Yes” or advancedupto equal to “the cecum”, then
cecalintub equal to “Yes.” To calculate the cecal intubation rate, patients with cecalintub
equal to “Yes” are divided by total patients.
3.7 Data analysis
3.7.1

Unit of analysis
To address the research questions, the unit of analysis is the patient. Because there

is only one procedure per patient in our sample, the number of colonoscopies” implies the
same number of patients.
3.7.2

Study period
Retrospective data on 20,540 screening colonoscopies from a licensed ambulatory

surgery center for endoscopy in South Carolina, performed during September 4, 2001 and
February 4, 2011 were analyzed.
3.7.3

Table of variables
The variables used are listed in Table 3-1. A total of twelve variables were used

from the procedure dataset and two variables were extracted from the polyp dataset. The
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variables are three categorical variables (patient age, patient race, and protocol type), six
dichotomous variables (patient gender, polyp found (or not), adenoma found, sedation
type, good bowel preparation (yes/no), and training procedure (yes/no), and three
continuous variables (number of polyps found in a patient, number of adenomas found in
a patient, and procedure time).
Two variables were extracted from polyp dataset, which were polyp size in
millimeter and polyp location. Each was summarized into procedure data set based on
procedureID, and hierarchically categorized into “no polyp”, “at least one small polyp
(≤5mm)”, “only medium polyps (6-9mm)”, and “only large polyps (10+mm) found” in a
patient; and “no polyp”, “at least one right-sided polyp found” or “only left-sided polyps
found” in a patient.
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Table 3-1 variables of interest
Variable name
Variable
description
Procedure dataset
PatAgeGrp
Patient age

Level of
variable

Variable categories

Type of
variable

4

Categorical

Dichotomous

PatGender
PatRace
protocol

Patient gender
Patient race
Protocol type

2
3
3

polyps

Does this patient
have any polyps?
Does this patient
have any
adenomas?
The number of
polyps detected for
this patient
The number of
adenomas detected
for this patient
Total procedure
time
Sedation type

2

<50 years, 50-59
years, 60-69 years,
70-89 years
Male, Female
White, Black, Other
1-person technique
specialist, 2-person
technique specialist,
2-person technique
PCP
Yes, No

2

Yes, No

Dichotomous

NA

NA

Continuous

NA

NA

Continuous

NA

NA

Continuous

2

Dichotomous

bowelprepgood

Bowel preparation
status

2

Training
procedure status

Is procedure a PCP 2
training
procedure? (<140th
procedure for the
PCP)

Midazolammeperdine, Propofol
Yes: If it was
Excellent, Good, Fair
bowel preparation
status
No: If it was Poor
bowel preparation
status
Yes: If it was 1-139th
procedure for the
PCP
No: >140th procedure
for PCP or any
specialist procedure.

adenoma

SumPolyps

SumAdenoma

TimeProc
Sedation

Polyp dataset
Polypsizemm

Polyp size in mm

4

Polyploc

Whether the polyp

3

Dichotomous
Categorical
Categorical

Dichotomous

Dichotomous

No polyp, ≦5 mm, 6- Ordinal
9 mm, 10+ mm
No polyp, left colon, Ordinal
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site is in the left
colon or the right
colon?

right colon

3.8 Statistical analysis
To answer the research questions, statistical models were run to examine
associations between the independent variables of interest and screening colonoscopy
quality indicators (dependent variables). Indicators studied are defined earlier. For the
protocol type, we compared the 1-person technique specialists group and the 2-person
technique specialists group with 2-person technique PCPs group. As for the sedation
type, we compared the propofol sedation procedures with midazolam-meperidine
sedation procedures. In each model, we controlled for bowel preparation status because
bowel preparation is a patient-dependent variable that greatly influences the quality
indicators. GEE modeling was used to account for patients clustered within physician.
SAS version 9.3 is used.
3.8.1

Model 1: Procedure time (continuous variable)

A linear GEE regression model was used to investigate protocol type/sedation type using
“proc genmod” syntax in SAS.
Yprocedure time=β0 + β1*2-person technique/physician specialty + β2*patient age +
β3*patient gender + β4*patient race + β5* number of polyps found + β6* sedation type
+ β7* bowel preparation + β8*sedation type*bowel preparation + β9*training
procedure status + εerror
This linear GEE regression model tested the association between protocol type (1person technique vs. 2-person technique) and the sedation type and the procedure
durations controlling for the remaining variables.
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For all models we tested the interaction term of sedation type with bowel
preparation and because it was statistically significant, we compared procedure times for
Midazolam-meperidine/Fair (bowel prep), Midazolam-meperidine/Excellent,
Propofol/Poor, Propofol/Fair, and Propofol/Excellent to Midazolam-meperidine/Poor.
However on comparing the models with the above categories with the two variables
modeled separately, the results were not substantially different, but readily interpretable.
Hence the latter results were used for interpretation.
3.8.2

Model 2: Polyp detection likelihood (dichotomous variable)

A logistic GEE regression model was used to investigate protocol type/sedation type
using “proc genmod” syntax in SAS.
Ypolyp detected =β0 + β1*2-person technique/physician specialty + β2*patient age +
β3*patient gender + β4*patient race + β5* sedation type + β6* bowel preparation +
β7*sedation type*bowel preparation + β8*training procedure status + εerror
This logistic GEE regression model tested the association between protocol type
(1-person technique vs. 2-person technique) and the sedation type and the polyp detection
controlling for the remaining variables.
3.8.3

Model 3: adenoma detection likelihood (dichotomous variable)

A logistic GEE regression model was used to investigate protocol type/sedation type
using “proc genmod” syntax in SAS.
Yadenoma detected=β0 + β1*2-person technique/physician specialty + β2*patient age +
β3*patient gender + β4*patient race + β5*sedation type + β6* bowel preparation +
β7*sedation type*bowel preparation + β8*training procedure status+ εerror
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This logistic GEE regression model tested the association between protocol type
(1-person technique vs. 2-person technique) and the sedation type and the adenoma
detection controlling for the remaining variables.
3.8.4

Model 4: Advanced neoplasms detection likelihood (dichotomous variable)

A logistic GEE regression model was used to investigate protocol type/sedation type
using “proc genmod” syntax in SAS.
Yadvanced neoplasms detected=β0 + β1*2-person technique/physician specialty + β2*patient
age + β3*patient gender + β4*patient race + β5*sedation type + β6* bowel preparation
+ β7*sedation type*bowel preparation + β8*training procedure status+ εerror
This logistic GEE regression model tested the association between protocol type
(1-person technique vs. 2-person technique)/sedation type and advanced neoplasm
detection likelihood controlling for the remaining variables.
3.8.5

Model 5: likelihood of finding additional polyps (ordinal variable)

An ordered logistic GEE regression model to investigate protocol type/sedation type
using “proc genmod” syntax with “dist=multinomial” option in SAS.
Ynumber of polyps found =β0 + β1*2-person technique/physician specialty + β2*patient age +
β3*patient gender + β4*patient race + β5* sedation type + β6* bowel preparation + β7*
sedation type*bowel preparation+ β8*training procedure status+ εerror
This ordered logistic GEE regression model tested the association between
protocol type (1-person technique vs. 2-person technique) and the sedation type and
likelihood of finding an additional polyp in a patient controlling for the remaining
variables.
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3.8.6

Model 6: likelihood of finding additional adenomas (ordinal variable)

An ordered logistic GEE regression model to investigate protocol type/sedation type
using “proc genmod” syntax with “dist=multinomial” option in SAS.
Ynumber of adenomas found =β0 + β1*2-person technique/physician specialty + β2*patient age
+ β3*patient gender + β4*patient race + β5* sedation type + β6* bowel preparation +
β7* sedation type*bowel preparation+ β8*training procedure status+ εerror
This ordered logistic GEE regression model will test the association between
protocol type (1-person technique vs. 2-person technique) and the sedation type and the
ability of finding an additional adenoma in a patient, which controls for the remaining
variables.
3.8.7

Model 7: right colon polyps (ordinal variable) likelihood

An ordered logistic GEE regression model was used to investigate protocol type/sedation
type using “proc genmod” syntax with “dist=multinomial” option in SAS.
Yat least one right colon polyp detected=β0 + β1*2-person technique/physician specialty +
β2*patient age + β3*patient gender + β4*patient race + β5* sedation type + β6* bowel
preparation + β7* sedation type*bowel preparation + β8*training procedure status +
εerror
This ordered logistic GEE regression model tested the association between
protocol type (1-person technique vs. 2-person technique PCPs and 2-person technique
specialists) and sedation type vs. the likelihood of a right colon polyp detection, which
controls for the remaining variables.
3.8.8

Model 8: likelihood of finding increasingly smaller polyps (ordinal variable)
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An ordinal logistic GEE regression model to investigate protocol type/sedation type using
“proc genmod” syntax with “dist=multinomial” option in SAS.
Ypolyp size =β0 + β1*2-person technique/physician specialty + β2*patient age +
β3*patient gender + β4*patient race + β5* sedation type + β6* bowel preparation + β7*
sedation type*bowel preparation+ β8*training procedure status+ εerror
This ordered logistic GEE regression model tested the association between
protocol type (1-person technique vs. 2-person technique) and the sedation type and the
likelihood of finding a small adenoma vs. medium adenoma and large adenoma in a
patient controlling for the remaining variables.
3.9 Preliminary review of sample distribution by key dependent variables
Sample distributions for the number of polyps and adenomas found in each
subject were cross tabulated by protocol type and sedation type in order to assess the
suitability of the variable categories for the planned analyses considering statistical power
and model convergence potential. The distributions and the subsequent changes in
variable categorization for the final analyses are presented below.
Table 3-2 shows that the number of polyps was missing for 117 patients (similarly
for the number of adenomas found in Table 3-5). Majority of the patients had no polyps
(38.5%), one polyp (31.5%), two polyps (16.5%), and three polyps (8%). Beyond three
polyps, the sample percentage (6%) is low. Therefore, we categorized patients into four
levels: 0, 1, 2, and 3+. Table 3-3 shows the breakdown of these four categories by
protocol type (1-person technique vs. 2-person technique with physician specialty). Based
on the distribution, the percentages in each cell appear reasonable except for 39 patients
with three or more polyps under the 1-person technique specialist group which could
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breakdown into zero cells in multiple regression analysis. Table 3-4 shows the
distribution of sedation type (Midazolam-meperidine vs. propofol) by number of polyps
found in four categories. The range was 29% to 39% of patients in each sedation type
with zero polyps or one polyp. The percentages of patients with zero or one polyp in
Midazolam-meperidine sedation were higher than propofol sedation, however, the pattern
was reversed for patients with two polyps and three and more polyps which are higher in
those with propofol sedation.
Table 3-5 shows the distribution of the number of adenomas found in a patient,
117 patients with missing polyp information. Table 3-6 and 3-7 showed the breakdown
by protocol type (1-person technique vs. 2-person technique with physician specialty) and
sedation type (Midazolam-meperidine vs. propofol). The patterns mostly mirrored the
number of polyps found.
Table 3-8 shows the distribution of the study sample by protocol type and
sedation type: 604 patients (3%) were served by 1-person technique specialist (two
specialists), 4,733 patients (23%) were served by 2-person technique specialist (three
specialists), and the majority of patients (15,203, 74%) were served by 2-person
technique PCP (54 PCPs). About 55% of the patients were provided Midazolammeperidine sedation and 45% of the patients provided propofol sedation. Most patients
were aged 50 to 59 years (45%), followed by 60 to 69 years (25%), <50 years (18%) and
70 to 89 years (12%). Slightly more females (54%) and Blacks (52%) were represented in
our study sample.
Table 3-9 and 3-10 shows the distribution of dependent variables by the major
independent variables of interest. These tables show the distribution of the sample in each
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cell relevant for multiple regression analysis. For example patients under 1-person
technique specialist with three or more polyps broken down by sedation type yielded only
five patients under Midazolam-meperidine sedation group. The sample distribution by
number of adenomas found is more extreme with only three patient in this category and
11 patients under the propofol sedation group.
The preliminary reviews of the sample distributions guided our scheme of
variable recoding and the models used to address our research questions.
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Table 3-2 Distribution of the number of polyps found per subject
Polyps found per subject
Frequency
Percentage(%)
Missing
117
0.57
0
7,772
37.84
1
6,383
31.08
2
3,346
16.29
3
1,634
7.96
4
716
3.49
5
323
1.57
6
134
0.65
7
64
0.31
8
25
0.12
9
15
0.07
10
3
0.01
11
6
0.03
13
1
0.00
14
1
0.00
Table 3-3 Distribution of the number of polyps found per subject by protocol type
Polyps found per
1-person technique
2-person technique
2-person technique
subject
specialist
specialist
PCP
Missing
2 (0.33%)
42 (0.89%)
73 (0.48%)
0
322 (53.31%)
1713 (36.19%)
5737 (37.74%)
1
174 (28.81%)
1480 (31.27%)
4729 (31.11%)
2
67 (11.09%)
765 (16.16%)
2514 (16.54%)
3+
39 (6.46%)
733 (15.49%)
2150 (14.14%)
Table 3-4 Distribution of the number of polyps found per subject by sedation type
Polyps found per subject Midazolam-meperidine Propofol
Missing
83 (0.74%)
34 (0.37%)
0
4,386 (38.93%)
3,386 (36.51%)
1
3,726 (33.07%)
2,657 (28.65%)
2
1,791 (15.90%)
1,555 (16.77%)
3+
1,280 (11.36%)
1,642 (17.71%)
Table 3-5 Distribution of the number of adenomas found per subject
Adenomas found per
Frequency
Percentage(%)
subject
Missing
117
0.57
0
14,003
68.17
1
4,054
19.74
2
1,456
7.09
3
557
2.71
4
225
1.10
5
73
0.36
90

6
7
8
9
11

29
13
7
5
1

0.14
0.06
0.03
0.02
0.00

Table 3-6 distribution of the number of adenomas found per subject by protocol type
Adenomas found per 1-person technique
2-person technique
2-person
subject
specialist
specialist
technique PCP
Missing
2 (0.33%)
42 (0.89%)
73 (0.48%)
0
459 (75.99%)
3,245 (68.56%)
10,299 (67.74%)
1
101 (16.72%)
911 (19.25%)
3,042 (20.01%)
2
28 (4.64%)
353 (7.46%)
1,075 (7.07%)
3+
14 (2.32%)
182 (3.85%)
714 (4.70%)
Table 3-7 Distribution of the number of adenomas found per subject by sedation type
Adenomas found per subject Midazolam-meperidine Propofol
Missing
83 (0.74%)
34 (0.37%)
0
7,706 (68.40%)
6,297 (67.90%)
1
2,224 (19.74%)
1,830 (19.73%)
2
814 (7.23%)
642 (6.92%)
3+
439 (3.90%)
471 (5.08%)
Table 3-8 Distribution of study sample by key independent variables
No. patients
n (%)
No. performing physicians
Protocol type
1-person technique specialist
604(2.94)
2
2-person technique specialist 4,733(23.04)
3
2-person technique PCP
15,203(74.02)
54
Sedation type
Midazolam-meperidine
11,266(54.85)
Propofol
9,274(45.15)
Patient age
<50 years
3,792(18.46)
50-59 years
9,138(44.49)
60-69 years
5,066(24.66)
70-89 years
2,544(12.39)
Patient gender*
Male
9,390(45.72)
Female
11,054(53.82)
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Patient Race*
Whites
Blacks
Other
Number of polyps found**
0
1
2
3+

9,139(44.49)
10,623(51.72)
682(3.32)
7,772(37.84)
6,383(31.08)
3,346(16.29)
2,922(14.23)

Table 3-9 Breakdown of study sample by key independent variables with the number of
polyps found
No.
No.
No.
patient
patients
patients
s
Protocol
polyp
n (%)
n (%)
n
type
sedation type
number
Midazolammissing
0
meperidine
0
164
1
78
1-person
2
15
techniqu
3+
5
262 (43.38)
e
604(2.94)
missing
2
specialis
0
158
t
1
96
2
52
Propofol
342 (56.62)
3+
34
Midazolammissing
32
meperidine
0
1073
1
910
2-person
2
389
2692
techniqu
(56.88)
3+
288
e
4,733(23.04)
missing
10
specialis
0
640
t
1
570
2
376
2041
Propofol
(43.12)
3+
445
Midazolammissing
51
2-person
15,203(74.02
meperidine
techniqu
0
3149
8312
)
e PCP
(54.67)
1
2738
92

2
3+
missing

6891(45.33
)

Propofol

0
1
2
3+

1387
987
22
2588
1991
1127
1163

Table 3-10 Breakdown of study sample by key independent variables with the number of
adenomas found
No.
No.
No.
patient
patients
patients
s
Protocol
adenoma
n (%)
n (%)
n
type
sedation type
number
Midazolammissing
0
meperidine
0
255
1
30
1-person
2
4
techniqu
262 (43.38)
3+
3
e
604(2.94)
missing
2
specialis
0
234
t
1
71
2
24
Propofol
342 (56.62)
3+
11
Midazolammissing
32
meperidine
0
1889
1
498
2-person
2
197
2692
techniqu
4,733(23.04
(56.88)
3+
76
e
)
missing
10
specialis
0
1356
t
1
413
2
156
2041
Propofol
(43.12)
3+
106
Midazolammissing
51
meperidine
0
5592
2-person
15,203(74.0
1
1696
techniqu
2)
2
613
8312
e PCP
(54.67)
3+
360
Propofol
6891(45.33 missing
22
93

)

94

0
1
2
3+

4707
1346
462
354

Chapter 4

CONCLUSIONS AND DISCUSSION

In lieu of chapter 4 and 5, the following manuscripts are included:
Manuscript #1: Does a hands-on 2-person colonoscopy technique affect screening
colonoscopy quality and outcomes of primary care physicians and specialists?
Abstract
Background: Colorectal cancer (CRC) is the third most prevalent cancer and 2nd leading
cause of cancer death in the U.S. Colonoscopy has been recommended as the preferred
screening method to prevent cancer by removing polyps before they transform into
cancer. Although the effectiveness of colonoscopy in preventing CRC is documented,
screening colonoscopy coverage in the US population remains low. This is partly due to
low colonoscopy capacity due to a shortage of gastroenterologists (GI). When the supply
of GIs is limited, training primary care physicians (PCP) effectively in screening
colonoscopy with quality assurance safeguards could be a solution to address the gap.
Objectives: To assess if the “hands-on” 2-person technique innovative clinical protocol
enables the quality of PCP-performed colnoscopies to be comparable to specialistperformed colonoscopies.
Methods: The study center, a state-licensed ambulatory surgery center, the South
Carolina Medical Endoscopy Center (SCMEC) requires an innovative 2-person technique
protocol for all PCPs all the time regardless of trained status. 59 physicians performed
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colonoscopies, the 2-person technique was consistently complied with by 57 physicians
(54 PCPs and 3 specialists), and 1-person technique was used by 2 non PCPs (one
colorectal surgeon and one general surgeon). 2-person technique will be examined for its
effect on the quality of screening colonoscopies. The study hypotheses is that screening
colonoscopy quality among the 2-person protocol group is better than among solo
technique protocol group. Only the screening colonoscopy procedures of all patients
served during this period. Subsequent (surveillance) procedures are not included as lesion
rates may be different at these procedures.
Results: About 3% of the patients were served by 1-person technique specialists, 23% by
2-person technique specialists, and the remaining 74% by 2-person technique PCPs. The
likelihood of polyp detection was highest for the 2-person technique specialists (adjusted
OR=1.39) compared to 2-person technique PCPs, and 1-person technique specialists were
79% less likely to detect a polyp(s) relative to 2-person technique PCPs (adjusted
OR=0.56). The effect is sustained for adenoma detection and for the likelihood of finding
each additional polyp/adenoma. Similarly, 2-person technique specialists were
significantly more likely to detect a right colon polyp than solo specialists (estimated OR:
2.42). The likelihood of finding small polyp(s) mirrors the pattern of quality indicators
described above.
The adjusted procedure time is longest for 2-person technique PCPs. Compared to 2person technique PCPs, 2-person technique specialists take an average of 1.01 minutes
(p=.184) shorter, while 1-person technique specialists use 3.77 minutes (p<.0001) shorter
time to finish the procedure controlling for other factors.
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Conclusions: This study finds that an innovation of a hands-on 2-person technique is
associated with superior colonoscopy performance and lesion detection outcomes, and
that by every discriminating measure, the results with the 2-person technique are
superior, and consistent across measures. A study limitation is the small numbers of 2
person technique specialists and 1-person technique specialists.
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Introduction
Colorectal cancer (CRC) is the 3rd most prevalent cancer and 2nd leading cause of
cancer death in the U.S. (SEER 2013). Colonoscopy has been recommended as the
preferred screening method to prevent cancer by removing polyps before they transform
into cancer (Rex 2000, Rex 2009, David 2006). Investigations have focused on adenoma
clearance for reducing the risk of developing CRC (Kaminski 2010, Rex 2006,
Lieberman 2007, Rex 2009). Although the effectiveness of colonoscopy in preventing
CRC is documented, screening colonoscopy coverage in the US population remains low.
This is partly due to low colonoscopy capacity due to a shortage of gastroenterologists
(GIs), the major physician type performing screening colonoscopies. There is a big gap
between GI supply and screening-eligible population (Seeff 2004). The annual new
addition of the aging baby boomer population keeps the gap growing. Currently, there are
about 13,968 board-certified GIs in the US, increasing annually by a count of 460 (less
retirements) (ABIM 2013). To cover 100% of all screening-eligible US population, an
estimated additional 7,340 GIs are needed (Vijan 2004).
When the supply of GIs is limited, trained primary care physicians (PCPs) could
be a solution to address the gap, especially for underserved populations and regions
(including rural areas). However, there is a widespread conviction that GIs being
specialized perform better in their specialty functions than non-GIs. Some studies support
this view. Non-GIs detected colorectal cancer in 87% of patients with a true cancer
compared to 97.3% for GIs, although this study did not report the results adjusted for
incomplete colonoscopy (Rex 1997). The authors also noted the lack of specific
information on a major factor, namely non-GI providers’ training in colonoscopy, noting
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that some of the study providers were self-trained and others had variable (no
documented) training. Examining colonoscopy quality by the ultimate outcome, CRC
incidence following colonoscopy, two Canadian studies reported that following
colonoscopies by non-GIs, the incidence of CRC was significantly higher compared to
colonoscopies by GIs (Rabeneck 2010, Bressler 2007).
In contrast, other research has shown that trained PCPs’ colonoscopy performance
is comparable with GIs (Wilkins 2009, Xirasagar 2009). Cecum intubation rates for PCPs
are documented at 96.5% (Edwards 2004), 89.2% (Wilkins 2009), and 98.1% (Xirasagar
2010), and adenoma detection rates (ADR) at 22.5% (Edwards 2004), 28.9% (Wilkins
2009), and 29.9% (Xirasagar 2010) provided by trained PCPs. Another series reported
that PCPs had an ADR of 27.2% in men and 21.4% in women (Newman 2005).
Training PCPs effectively in screening colonoscopy with quality assurance
safeguards may be a solution to cover the unscreened population. However, the uptake of
colonoscopy by PCPs remains very low. Only 4% of graduating family medicine
residents applied for colonoscopy credentialing in 2002 although half of the residency
programs offered it, and only 18% of these programs had any candidate registered for the
training (Wilkins 2004). While research has documented that “trained” PCPs can provide
competent and safe colonoscopy (Edwards 2004, Newman 2005, Wilkins 2009,
Xirasagar 2010), there is no documentation of the training process or the clinical
protocols used by high-performing PCPs. This study presents the effectiveness of two
protocol elements that were consistently used and documented at the endoscopy center to
train PCPs. This protocol requires a hands-on 2-person technique, and includes other
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elements to maximize colon surface inspection and to minimize the likelihood of missing
polyps.
The 2-person technique used by the study center may be important because
fatigue is a likely factor in adenoma detection rates, particularly as day progresses.
Physicians’ ADR for afternoon procedures were significantly lower than for their own
morning procedures (25.3% vs. 29.3%, p=.008) (Sanaka 2009). The phenomenon of
potentially lower quality performance due to fatigue is not limited to physicians. A study
of the judicial system on the association between a favorable parole ruling and timing of
the review (morning vs. afternoon) showed that judges were more likely to issue a
favorable parole ruling in the mornings than in the afternoon, and immediately after the
lunch break than in the later afternoons. The authors suggested that mental fatigue may
be less at the beginning of the work day and after a short break for a meal or rest
(Danziger 2011). In the case of colonoscopies, studies show that having a second
observer in the procedure room is associated with higher ADR/polyp detection rates
(PDR), while one person performs the procedure (either the fellow or the attending GI),
having the other as observer significantly increased the ADR, 37% vs. 23% (p<.01)
among screening colonoscopies (Rogart 2008). Another retrospective study that was not
limited to screening colonoscopies reported that the detection rate for small adenoma
(<5mm) was significantly higher when there is a second observer (25%vs. 17%, p=.001)
noting that the rate and independent performance was higher for non-experienced fellows
(second and third-year fellows) (Buchner 2011).
One advantage of having a second observer watching the video screen is reduced
likelihood of missed lesions due to visual fatigue. Supporting this explanation is one
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study of a dedicated endoscopy nurse observing the video screen while the attending
physician performed the screening colonoscopy. This study showed significantly more
polyps detected per patient (adjusted OR=1.26) than when the attending physician
performed solo with no observer (Aslanian 2013).
Experience level of the performer is an additional factor in performance quality.
Peters et al (2010) reported that senior (third year) fellows supervised by the attending
physician had almost double the ADRs of junior fellows (OR =1.7). A study from Korea
noted that an endoscopy nurse observer of the video screen increased the likelihood of
finding a lesion (OR =1.58 for polyp, and 1.47 for adenoma), when a fellow performed
the procedure even though it was their 150th-500th procedures (OR =2.07), but no
increase was observed for senior attending GIs (Lee 2011).
In contrast to the above studies, a non-randomized prospective study conducted at
a single-center reported no significant difference in polyp detection rates with an
additional observer (single, attending GI alone 32%, second observer with fellow
performing and attending GI supervising, 33%) and in adenoma detection rates (19.3% vs
14.9%) (Eckardt 2009). When the GI performed solo they removed fewer diminutive (<5
mm) hyperplastic polyps but relatively more adenomas than fellows.
To our knowledge, the documented “2-person technique” studies have had similar
protocols, namely, having a second observer. In our study setting, the protocol requires a
“hands-on” 2-person technique to compensate for the lack of specialist training of the
PCPs which may confer additional advantages that solo performing GIs do not have.
Additionally prior studies on the 2-person technique protocols were also associated with
the conventional polyp search limited to the phase of withdrawing the colonoscope. Our
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study setting, in addition of the hands-on 2-person technique requires for PCPs, also
requires gradual insertion and withdrawal of the colonoscope with polyp search and
removal during both insertion and withdrawal to maximize coverage of all mucosal
surface. This latter requirement also minimizes chances of “losing” a polyp that may be
encountered during insertion but not traceable during the withdrawal phase, which is the
phase when gastroenterologists typically perform polypectomy. However, large polyps
are removed only during withdrawal as hemorrhage may lead to aborting the procedure if
removal is attempted during insertion. Because of the major differences, the 2-person
technique protocol in our study setting is unique and being applied to PCPs, the question
arises, does this technique enable the quality of PCP-performed colonoscopies to be
comparable to specialist-performed colonoscopies? Secondly, within specialists/experts,
does the hands-on 2-person technique improve ADRs?
Methods
The study center, a state-licensed ambulatory surgery center, the South Carolina
Medical Endoscopy Center (SCMEC) has trained 54 PCPs since 2001 in colonoscopy
with 140 training procedures supervised by specialists/experts credentialed in screening
colonoscopy, subsequent colonoscopies by PCPs at the center require adherence to the
prescribed protocol, with the specialist always available on site for rescue assistance
(therapeutic assistance to remove advanced adenomas, polyps at difficult locations,
control bleeding, and/or manage spasms). The Center protocol requires a 2-person
technique for all PCPs all the time regardless of trained status. Over the study period,
September 4, 2001 through February 4, 2011, 59 physicians performed colonoscopies,
the 2-person technique was consistently complied with by 57 physicians (54 PCPs and 3
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specialists), and 1-person technique was used by 2 non PCPs (one colorectal surgeon and
one general surgeon), PCPs are defined as those with family medicine, internal medicine,
pediatrics or obstetrics/gynecology specialization (Figure 4-1).
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20,912 patients between September 4, 2001 and February 4, 2011
342 <30 years & ≥90
20,570 patients with
initial colonoscopy 3089 years
30 excludes dues to prior
history of colon/rectum
resection

20,540 study

604 patients with 1person technique

15,203 patients with
2-person technique

4,773 patients with 2person technique

Figure 4-1: Study sample selection flowchart
The innovative 2-person technique protocol requires an endoscopy technician to
advance the colonoscope while the performing physician manipulates the scope tip for
polyp search and removal. This method has the additional advantage of avoiding missing
polyps due to physician's motor fatigue particularly of the left or non-dominant hand. It
confers the dexterity of two “right” hands (of the two participants) for polyp search and
removal, and further, ensures more persons watching the video screen for polyps. The
study center has used propofol sedation since April 1, 2006 instead of the conventional
midazolam-meperidine (MM) combination sedation. 2-person technique will be
examined for its effect on the quality of screening colonoscopies. Additional protocol
features followed in all 2-person technique procedures are: a) gradual insertion and
withdrawal for polyp search and removal to maximize coverage of the colonic mucosal
surface, b) at least 3 persons watching the video screen.
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The study hypotheses is that screening colonoscopy quality among the 2-person
protocol group is better than among solo technique protocol group. Our dependent
variables of interest representing procedure quality are following: likelihood of polyp
detection (Yes vs. No), likelihood of adenoma detection (Yes vs. No), the likelihood of
advanced neoplasms detection (Yes vs. No), likelihood of additional polyps detected in
subjects (0, 1, 2+), likelihood of additional adenomas detected in subjects (0, 1, 2+),
likelihood of detecting small polyps (No polyp, Small (≤5mm), Medium (6-9mm), Large
(10+mm)), likelihood of detecting right-sided polyp (polyp location in the cecum,
ascending colon, hepatic flexure, or transverse colon proximal to the splenic flexure; No
polyp, Left only, At least one right polyp) , and the procedure time.
Our statistical analyses must address non-independence of data due to clustering
of patients within physician. We expect physician effects to be similar within their patient
group (for example, each physician’s dexterity of hand movements) but no systematic
distribution of physician effects across physicians. Therefore, we use generalized
estimating equations (GEE) modeling. This method assumes a specific correlation
structure of the repeated measures data within physician, in this case, an exchangeable
correlation structure. This structure assumes that any two observations from different
physicians are uncorrelated, and any two observations from the same physician are
correlated at the same value (no matter within which physician the observations arise).
GEE was used because it accommodates within-physician correlation without focusing
attention on that aspect of the data analysis. The within physician correlation is treated as
an ancillary problem for which to be accounted but is not of profound interest. When
using the exchangeable correlation structure for a linear model, the regression parameters
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of the GEE are algebraically equivalent to the association among patients within a
physician panel. The same is not quite true for inference of regression parameters from
the logistic GEE and logistic random effect models. GEE was determined to be the
preferred modeling tool for these analyses.
Only the screening colonoscopy procedures of all patients served during this
period. Subsequent (surveillance) procedures are not included as lesion rates may be
different at these procedures. Linear GEE regression was used to study the association
between the procedure time and our variables of interest. Logistic GEE regression was
applied to test the hypotheses regarding likelihood of any lesion detected. The ordered
logistic GEE regression was used to test whether the likelihood of finding additional
polyp(s)/adenoma(s) in a subject, right colon polyp(s), and smaller polyp(s) in a patient
increased with the use of the 2-person technique. The score test was used to verify the
assumption of ordered logistic regression.
Results
The demographic distribution of the study sample 20,540 patients and by provider
type is shown in Table 4-1. About 3% of the patients were under 1-person technique
specialist, 23% of the patients were under 2-person technique specialist, and the
remaining 74% of the patients were using 2-person technique PCP. Female (53%) and
Blacks (51%) were slightly preponderant in the study cohort, and 7,772 (37.84%) patients
had no polyps.
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Table 4-1: Demographic and procedure characteristics of the study sample
No. patients
n (%)
Cecum intubation rate (% of cases)
96.48%
Protocol type
1-person technique specialist
604 (2.94)
2-person technique specialist
4,733 (23.04)
2-person technique PCP
15,203 (74.02)
Patient age
<50 years
3,792(18.46)
50-59 years
9,138(44.49)
60-69 years
5,066(24.66)
70-89 years
2,544(12.39)
Patient gender*
Male
9,390(45.72)
Female
11,054(53.82)
Patient Race*
Whites
9,139(44.49)
Blacks
10,623(51.72)
Other
682(3.32)
Number of polyp found**
0
7,772 (37.84)
1
6,383 (31.08)
2+
6,268 (30.52)
Polyp size†
No polyps
7,772 (37.84)
11,727 (57.09)
Small (≦5mm)
Medium (6-9mm)
591 (2.88)
Large (10+mm)
377 (1.84)
Polyp anatomic location†
No polyps
7,772 (37.84)
Left colon
6,387 (31.10)
Right colon
6,273 (30.54)
* Total of 96 patients missing information on gender and race.
**Total of 117 patients with missing information on number of polyps.
† 73 patients had missing polyp size information, 108 patients were missing information on polyp
anatomic location.
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Table 4-2 shows the sample distribution by quality indicators. The PDR and the
mean number of polyps detected per subject (MNP) for solo performing specialists is
lower with PDR: 46.7% and MNP: 0.74 compared to 2-person technique specialists
63.8% and 1.23, and 2-person technique PCPs 62.3% and 1.18, respectively. Adenoma
detection for the 3 groups mostly mirrors the polyp detection pattern, being 23.7%,
30.6%, and 31.8% rates for the respective groups, and MNA 0.34, 0.49, and 0.52
respectively. Mean procedure time is shortest in the 1-person technique group (19.68
minutes) higher for 2-person technique specialists (24.78 minutes), and highest for 2person technique PCP (26.21 minutes). Breaking down to procedures with polyps and
without polyps found, the pattern of procedure time differences are sustained. Compared
to solo performers (38.74%), the 2-person technique groups found small, ≤5mm polyps in
larger proportions of patients (PCP: 57.23%, specialist: 58.99%). Similarly, solo
performance specialists have lower proportion right colon polyp detected (19.04%)
compared to the 2-person technique groups (PCP: 30.74%, specialist: 31.35%).
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Table 4-2: Indicators of colonoscopy quality by procedure protocol
1-person
2-person
2-person
technique
technique
technique
specialists
specialists
PCPs
mean / n(%)
mean / n(%) mean / n(%)
No. of performing physicians
2
3
54
Cecum intubation rate (% of
87.91%
93.24%
97.83%
cases)
Lesion detection rates
Polyp detection rate (% of
46.69
63.81
62.26
cases)*
Number of polyps detected
0.74±1.02
1.23±1.39
1.18±1.36
per subject (mean, SD)*
Adenoma detection rate (%
23.68
30.55
31.78
of cases)*
Number of adenomas
0.34±0.74
0.49±0.90
0.52±0.95
detected per subject (mean,
SD)*
Advanced neoplasms (% of
6.79
6.44
6.85
cases)*
Procedure duration
All colonoscopies
Total procedure time
19.68±8.74
24.78±22.56 26.21±12.13
(min)*
Colonoscopies with no polyp
found
Total procedure time
17.58±6.57
21.66±12.74 22.02±10.24
(min)*
Colonoscopies with polyp(s)
found
Total procedure time
21.97±10.14
26.23±25.75 28.67±12.47
(min)*
Polyp size*†
No polyps
53.31
36.19
37.74
38.74
58.99
57.23
Small (≦ 5 mm)
Medium (6 – 9 mm)
3.64
2.45
2.98
Large (10+ mm)
2.98
2.09
1.71
Polyp anatomic location*†
No polyps
53.31
36.19
37.74
Left colon
27.65
32.45
30.81
Right colon
19.04
31.35
30.74

p-value

P<.0001

P<.0001
P<.0001
P<.0001
P<.0001

P=.017

P<.0001

P<.0001

P<.0001
P<.0001

P<.0001

† 73 patients had missing polyp size information, 108 patients were missing information on polyp
anatomic location.
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Table 4-3 and Table 4-4 present multiple regression analyses of the associations
between technique and the variables of interest. The adjusted procedure time is longest
for 2-person technique PCPs. Compared to 2-person technique PCPs, 2-person technique
specialists take an average of 1.01 minutes (p=.184) less, while 1-person technique
specialists took 3.77 minutes (p<.0001) less time for the procedure, controlling for other
factors. The adjusted procedure time was longer for older patients (60 – 69 years: 2.06
mins, p<.0001; 70 – 89 years: 2.93 minus, p<.0001) compared to <50 years. Females had
longer procedure time (1.11 mins, p<.0001), and if the procedure was a PCP training
procedure (≤140procedures), it was longer (3.93 mins, p<.0001), as also for each
additional polyp found (3.16 mins, p<.0001).
The likelihood of polyp detection was highest for 2-person technique specialist
procedures (adjusted OR=1.39) compared to 2-person technique PCPs. The 1-person
technique specialists had 79% less likelihood of detecting a polyp(s) than 2-person
technique PCPs (adjusted OR=0.56). The effect is sustained for the adenoma yield.
Compared to 2-person technique PCPs, solo technique specialists were 37% less likely to
chance in detecting adenoma(s) (adjusted OR: 0.73, p=.005). Specialists using the 2person technique have a significantly higher likelihood of detecting adenoma(s) (adjusted
OR: 1.23, p<.0001). For advanced neoplasm(s), there was no difference between solo
performing specialists and 2-person technique PCPs (adjusted OR: 1.05, p=.811). But 2person technique specialists were slightly more likely to find an advanced neoplasm(s)
(adjusted OR: 1.14, p=.008).
The likelihood of finding a polyp or an additional polyp (given the first polyp) for
2-person technique PCP is 85% higher relative to 1-person technique specialist (adjusted
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OR 0.54, 95%CI: 0.36, 0.80). Within specialists, 2-person technique specialists were
much more likely to find an additional polyp than 1-person technique specialists
(adjusted OR: 2.48). The adjusted OR for 2-person technique specialists vs. 2-person
technique PCPs was 1.34 (95%CI: 1.16, 1.54). This pattern was sustained for the
likelihood of finding each additional adenoma, and within specialists, 2-person technique
was significantly more likely to be associated with finding each additional adenoma than
relative to solo specialist performance (adjusted OR: 1.73).
Because right-sided colon polyps are more likely to be missed (Bressler 2004,
Hewett 2011), polyp anatomic location was modeled. The likelihood of finding right
colon polyp(s) by solo performing specialists was 82% lower than 2-person technique
PCPs (OR: 0.55 for 1-person technique specialists). Similar to the findings on other
indicators, 2-person technique specialists were significantly more likely to detect a right
colon polyp than solo performing specialists (estimated OR: 2.42).
The likelihood of finding small polyp(s) mirrors the pattern of quality indicators
described above. Solo technique specialists were significantly less likely to find a small
(≤5mm) polyps than 2-person PCPs (adjusted OR: 0.52, 95%CI: 0.36, 0.77) and 2-person
technique specialists were the most likely to find increasingly smaller polyp(s) (adjusted
OR: 1.36, 95%CI: 1.18, 1.56). We did not model cecum intubation rate as a quality
indicator because the rate was 96.48% for the sample, and 93.24%, 97.83% and 87.91%
for the 2-person technique specialists, 2-person technique PCPs, and solo performing
specialists.
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Table 4-3: Adjusted estimates of colonoscopy performance and outcome quality
indicators by protocol type***
Dependent variables (colonoscopy quality indicators)
Procedure
Likelihood of
Likelihood of
Likelihood of
time (mins) finding polyp(s)
finding an
finding an advanced
(logistic GEE) †
adenoma(s)
neoplasm(s)
(logistic GEE) †
(logistic GEE) †
β p-value OR 95%CI
OR
95%CI
OR
95%CI
Protocol type
1-person
-3.77 P<.0001 0.56 0.37,0.83 0.73 0.38,1.38 1.05
0.69,1.59
technique
specialist
2-person
-1.01 P=.184 1.39 1.19,1.62 1.23 1.12,1.34 1.14
1.04,1.26
technique
specialist
2-person
0
0
1.00
1.00
1.00
1.00
1.00
1.00
technique
PCP
Patient age
<50 years
0
0
1.00
1.00
1.00
1.00
1.00
1.00
50-59 years 0.52 P=.166 1.33 1.21,1.47 1.51 1.35,1.68 1.31
1.08,1.60
60-69 years 2.06 P<.0001 1.61 1.48,1.75 2.17 1.97,2.38 1.81
1.54,2.13
70-89 years 2.93 P<.0001 1.83 1.60,2.09 3.02 2.69,3.38 2.17
1.75,2.70
Patient gender**
Male
0
0
1.00
1.00
1.00
1.00
1.00
1.00
Female
1.11 P<.0001 0.75 0.70,0.80 0.64 0.60,0.68 0.65
0.57,0.74
Patient race**
Whites
0
0
1.00
1.00
1.00
1.00
1.00
1.00
Blacks
-0.86 P=.082 0.90 0.80,1.01 0.88 0.81,0.97 1.03
0.90,1.17
Other
0.65 P=.202 0.89 0.73,1.10 0.84 0.69,1.01 0.79
0.55,1.15
th
Was this a PCP training procedure? (≤140 procedure for the PCP)
Yes
0
0
1.00
1.00
1.00
1.00
1.00
1.00
No
-3.93 P<.0001 0.92 0.80,1.05 0.90 0.81,0.99 0.88
0.75,1.02
Number of 3.16 P<.0001 polyps found
** Total of 96 patients was missing information on gender and race and excluded from analysis.
*** Models controlled for sedation type and bowel preparation status.
† Categories modeled are “No” and “Yes”.
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Table 4-4: Adjusted estimates of colonoscopy performance and outcome quality
indicators by protocol type*
Dependent variables (colonoscopy quality indicators)
Likelihood of
Likelihood of
Likelihood of
Likelihood of
finding an
finding an
finding at least one
finding
right colon
increasingly
additional polyp†
additional
polyp(s)
smaller polyp(s)
adenoma†
(ordered logistic (ordered logistic
GEE) ††
GEE) †††
OR
95%CI
OR
95%CI
OR
95%CI
OR
95%CI
Protocol type
1-person
0.54 0.36,0.80 0.71 0.37,1.38 0.55 0.34,0.90 0.52 0.36,0.77
technique
specialist
2-person
1.34 1.16,1.54 1.23 1.12.1.35 1.33 1.12,1.58 1.36 1.18,1.56
technique
specialist
2-person
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
technique
PCP
Patient age
<50 years 1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
50-59 years 1.33 1.22,1.45 1.52 1.37,1.69 1.38 1.26,1.51 1.31 1.20,1.44
60-69 years 1.68 1.55,1.81 2.26 2.06,2.48 1.79 1.67,1.92 1.55 1.43,1.68
70-89 years 1.87 1.66,2.10 3.15 2.82,3.51 2.20 1.97,2.46 1.72 1.51,1.95
Patient gender**
Male
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
Female
0.73 0.68,0.78 0.62 0.59,0.66 0.72 0.68,0.77 0.78 0.72,0.83
Patient race**
Whites
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
Blacks
0.87 0.78,0.97 0.89 0.81,0.97 0.92 0.83,1.02 0.89 0.79,1.00
Other
0.85 0.70,1.02 0.84 0.69,1.02 0.85 0.71,1.02 0.93 0.76,1.13
Was this a PCP training procedure? (≤140th procedure for the PCP)
Yes
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
No
0.92 0.80,1.06 0.89 0.81,0.99 0.93 0.81,1.05 0.93 0.81,1.07
* The model controlling for sedation type and bowel preparation.
** Total of 96 patients missing information on gender and race.
† Categories modeled are 0, 1, 2+.
†† Categories modeled are “No polyp”, “Left only”, “at least one Right polyp”.
††† Categories modeled are “No polyp”, “Small”, “Medium”, “Large”.
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Discussion
This study finds that an innovation of a hands-on 2-person technique is highly
associated with superior colonoscopy performance and lesion detection outcomes, and
that by every discriminating measure, the results with the 2-person technique are
superior, and consistent across measures. The polyp yield is much higher with 2-person
technique PCPs than with 1-person technique specialists, which is by far the most
widespread protocol in routine screening colonoscopies. Consistent with the literature of
high competent performance by trained family physicians (Edwards 2004). The effect
remains significant even when considering adenoma yields and advanced neoplasms
yields, which indicates that PCPs are able to distinguish adenomas from normal tissue
polyps on a similar scale as specialists.
With the help of another element of this study center’s innovative protocol, which
requires the polyp search and removal in both ways in and out and the gradual spiral
withdrawal, chance of missing the polyps is proposed to be lower. Because the routine
protocol performs polypectomy when withdrawing the colonoscope even if polyps were
detected in insertion period, this might highly missed the polyps because most of the
time, physicians cannot find the polyps after coming back due to the distortion of the
colon or mistakenly locate the polyps in memory. Polyp and adenoma detections are
consistently higher in 2-person technique groups, with regard to the number of
polyps/adenomas detected in a patient, the 2-person technique groups still have higher
chance of detecting more polyps/adenomas. This tells us that 2-person technique protocol
is not only superior in detecting a/an polyp/adenoma, but also trying to catch any
polyps/adenomas to make screening colonoscopy more beneficial in colorectal cancer
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prevention to the patients. Regarding to the polyp anatomic location, a constant relation
was observed, 2-person technique groups (PCPs: 1.82, specialists: 2.42, respectively) are
about 2 times more likely to detect right colon polyps than 1-person technique specialist.
Therefore, we are confident to state that 2-person technique protocol offers physicians to
perform a thorough colon inspection and this is evenly improved both in the left and right
colon. No specific segment of colon was favored.
When comparing among specialists, those under 2-person technique protocol are
consistently showing about 2-fold yields than those under 1-person technique protocol
with regard to the quality indicators we studied. The 2-person technique protocol plays an
important role in improving the colon clearance even among specialists by providing an
additional person with hands-on assistance in manipulating the colonoscope to convey
two dominant hands for errors caused by motor fatigue (Rogart 2008, Sanaka 2009,
Buchner 2011) and more persons watching on the video screens for polyp search to
reduce vision errors (Aslanian 2013). These elements of 2-person technique protocol
render the warranty of a thorough colon inspection, so that the missed chance reduces
with potential colorectal cancer protection increases.
This study suggests that the 2-person technique by PCPs with onsite specialist
support may be a solution to the insufficient colonoscopy capacity which stands in the
way of realizing the CRC prevention benefits of colonoscopy (Seeff 2006). PCPs
performing colonoscopy has been debated due to the lack of specialty training. The study
center provides PCPs a training program since 2001 and the unique element of 2-person
technique protocol improves the colonoscopy quality in general, the 2-person technique
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for PCPs rebuts the controversy of the inferiority of PCP colonoscopy quality in the
literature (Rex 1997Rabneck 2010, Bressler 2007).
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Manuscript #2: Does sedation type (midazolam-meperidine vs. Propofol) affect
screening colonoscopy performance quality and polyp detection outcomes?
Abstract
Background: Over the past decade the age-adjusted colorectal cancer (CRC) incidence
has significantly decreased. Most CRC cases and deaths can potentially be prevented by
colonoscopy screening which enables both primary prevention through removal of precancerous polyps and secondary prevention through early detection of cancer cases.
However the at-risk population’s uptake of screening colonoscopy has been less than
optimal. One reason could be public perceptions of colonoscopy as an invasive and
potentially painful procedure, particularly concerns about partially or unsedated
colonoscopy. Offering deep sedation which is documented to provide a well anesthetized
procedure experience and to alleviate patient fear of comfort may increase the
acceptability of colonoscopy. There is little systematic documentation of how sedation
type affects colonoscopy performance quality and lesion detection outcomes. It is
important to systematically study whether deep sedation independently improves
colonoscopy performance quality in ways that significantly impacts its CRC prevention
potential.
Objectives: This study examines the effect of propofol sedation relative to midazolammeperidine (MM) sedation in a setting where a high-performance, polyp detectionmaximizing colonoscopy protocol has been in place for 10 years.
Methods: Retrospective cohort study of all screening colonoscopies done at a statelicensed ambulatory surgery endoscopy center in South Carolina from September 4, 2001
and February 4, 2011. Propofol sedation in lieu of MM sedation was implemented since
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April 1, 2006. Because all other clinical protocol and patient navigation elements were
consistently implemented, these series enable the study of the independent associations of
propofol sedation with procedure quality and lesion detection outcomes. Patient is the
unit of analysis. The dependent variables representing procedure quality and outcomes
are procedure time and lesion detection captured at several levels of difficulty. The key
independent variable of interest is sedation type (propofol or MM).
Our study hypothesizes that propofol sedation is more likely to be associated with
finding a polyp/adenoma relative to no polyp/adenoma, and the same odds applies to
finding each additional polyp/adenoma Bowel preparation status significantly affects
procedure completion and therefore lesion detection rates. Therefore in assessing the
effectiveness of sedation type it is essential to adjust for bowel preparation status.
Results: Of total 20,540 study-eligible patients provided a screening colonoscopy from
September 4, 2001 through February 4, 2011, 11,266 patients were sedated with MM
(54.85%, all pre-April 1, 2006), and 9,274 patients with propofol (45.15%, from April 1,
2006). The polyp detection rate was higher in propofol-sedated patients (63.49%)
compared to MM (61.07%, p<.05), as was the mean number of polyps found per patient
(1.33 vs. 1.06, p<.0001), with similar differences in most lesion detection indicators.
Mean procedure time was shorter with propofol sedation (25.08 vs. 26.25 min for MM).
Propofol sedation was associated with slightly higher odds of finding an advanced
neoplasm (adjusted OR: 1.14, 95%CI: 1.01, 1.29) and with finding an additional polyp
(adjusted OR: 1.25, 95%CI: 1.07, 1.46) compared to MM sedation.
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Conclusions: Propofol sedation may contribute marginally to improved colonoscopy
quality, although quality improvement efforts may be better rewarded if focused on
measures to improve patient bowel preparation including patient navigation.
Introduction
Over the past decade the age-adjusted colorectal cancer (CRC) incidence
decreased from 51.8/100,000 in 1999 to 44.7/100,000 in 2009, and the age-adjusted
decreased from 20.5/100,000 to 16.9/100,000 (SEER 2013). Despite these reductions,
CRC remains a significant public health problem, affecting over 5% of Americans over
their lifetime (U.S. Cancer Statistics Working Group 2013) and killing 50% more
Americans than motor vehicle accidents (NHTSA 2012). Colonoscopy is recommended
as the preferred screening method because it enables primary prevention through removal
of pre-cancerous polyps (Rex 2000, Davila 2006, Rex 2009). However the uptake of
colonoscopy by at-risk population (aged 50 years or older, 40 years for those with a
family history of CRC) has been less than optimal, being 13.4% in 2005 and 36.4% in
2010 (calculated from the National Health Interview Survey 2005 and 2010 data).
One reason for low uptake of colonoscopy could be perceptions of colonoscopy as
an invasive and potentially painful procedure, particularly concerns about partially
sedated or unsedated colonoscopy, limiting CRC prevention efforts (Rex & Khalfan
2005, Sipe, Rex, Latinovich 2002). Offering deep sedation which is documented to
provide a well anesthetized procedure experience and to alleviate patient fear of
discomfort (Sipe, Rex, Latinovich 2002, Heuss 2004) may increase the acceptability of
colonoscopy. However deep sedation entails additional costs, notably personnel cost
(nurse anesthetists). Payers are more likely to cover costs that facilitate better quality and
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colonic clearance of polyps enhancing the CRC prevention impact of colonoscopies,
which in turn would reduce future treatment costs from the CRC cases prevented.
There is little systematic documentation of how sedation type affects colonoscopy
performance quality and polyp detection outcomes. The available evidence is mixed,
based on retrospective studies of procedure series that were not standardized for other
protocol elements that greatly impact the reported outcomes. Three studies of important
quality indicators, procedure completion rate (cecal intubation), and adenoma detection
rate showed positive associations with deeper sedation relative to mild sedation (Chelazzi
2009, Radaelli 2008, Wang 2010), while three others showed no significant associations
(Paspatis 2011, Rex 2012, Metwally 2011, Bannert 2012). Chelazzi et al (2009) reported
100% procedure completion rate under propofol sedation compared to 91.1% for nonsedated procedures (p<.05), with 1.5 minutes shorter insertion time the propofol group (9
minutes) than the non-sedated group (p=.0086). Radaelli et al reported the highest odds
of cecal intubation with propofol sedation (OR =2.36 relative to the non-sedated group),
followed by benzodiazepine-opiate (OR =2.13), and benzodiazepine alone (OR =1.46).
They also reported a similar pattern of increasing polyp detection with increasing
sedation (highest likelihood of detection with propofol sedation (OR=1.32) followed by
benzodiazepines (OR =1.12). A study of midazolam and pethidine used in specified doses
to produce moderate (MS) and deep sedation (DS) found no significant difference in the
polyp detection rate (MS: 61.5%, DS: 63.6%), adenoma detection rate (MS: 59.5%, DS:
60.4%), and right colon polyp detection rate (MS: 34.4%, DS: 36.8%) (Paspatis 2011).
Another study found no difference in adenoma detection rates of procedures sedated by
propofol vs. midazolam/fentanyl (Metwally 2011). A retrospective cohort study across 72
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facilities reported a somewhat higher polyp detection rate with moderate sedation than
with deep sedation (37.7% vs. 34.1%, p<.0001) but lower advanced adenoma detection
(6% vs. 7.2%, p=.01), the latter effect being greater in facilities where deep sedation
procedures exceeded 10% of their respective total procedures (7.5% vs. 5.7%, p=.003)
(Wang 2010). None of the studies reported on propofol sedation compared to the most
commonly used sedation type, midazolam-meperidine.
The evidence on procedure completion and adenoma detection rates by sedation
type/level remains mixed. However, the evidence is clear regarding patient satisfaction
with pain control. All propofol-sedated patients reported no pain (102 out of 102
patients), compared to 17 out of 23 persons in the midazolam group, and 11 out of 22 in
the no sedation group (Gasparovic 2003).
The above evidence suggests that deep sedation by propofol may be time saving
and it achieves full pain control compared to other sedatives. The mixed results for other
colonoscopy quality indicators are reasonably attributable to the documented widely
variable colonoscopy protocols and performance preferences of endoscopists (Barclay
2006, Rex 2001). It is important to systematically study whether deep sedation
independently improves colonoscopy performance quality in ways that significantly
impacts its CRC prevention potential. This is a key issue of interest to medical
professionals and payers. This study addresses this need by examining the effect of
propofol sedation relative to midazolam-meperidine (MM) sedation in a setting where a
high-performance, polyp detection-maximizing colonoscopy protocol has been in place
for 10 years. (The details of these clinical protocol elements are described in a previous
paper.) All providers either adhered to the colonoscopy protocol (57 of 59) or were
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identified as non-adherent, and uniform patient navigation to reinforce bowel preparation
instructions was provided to all patients. The center has maintained rigorous
documentation of procedures and outcomes since 2001 enabling a systematic study of the
independent associations of propofol sedation (instituted for all center procedures since
April 1 2006) with procedure quality and lesion detection outcomes, by comparing
propofol sedated procedures with MM procedures (pre-April 1, 2006).
Methods
This is a retrospective cohort study of all screening colonoscopies done at a statelicensed ambulatory surgery endoscopy center in South Carolina from September 4, 2001
and February 4, 2011. Propofol sedation in lieu of MM sedation was implemented since
April 1, 2006. Because all other clinical protocol and patient navigation elements were
consistently implemented, these series enable the study of the independent associations of
propofol sedation with procedure quality and lesion detection outcomes. Patient is the
unit of analysis of. Of total 20,912 patients, 20,540 patients were study-eligible after
excluding 342 patients aged less than 30 years and over 89 years, and 30 patients with a
prior history of colon/rectum resection. The sample selection flow chart is shown in
Figure 4-2.
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26,523 procedures as
of February 4, 2011
5,611 2nd and later procedures
20,912 initial procedures
342 <30 years & ≥90 years
20,570 patients with initial
colonoscopy 30-89 years
30 excludes dues to prior history
of colon/rectum resection
20,540 study eligible

9,274 patients with
Propofol sedation

11,266 patients with Midazolammeperdine sedation
Figure 4-2: Sample selection flowchart

The dependent variables representing procedure quality and outcomes are as
follows: likelihood of finding a polyp (Yes vs. No), likelihood of finding an adenoma
(Yes vs. No), likelihood of finding an advanced neoplasm (Yes vs. No), likelihood of
finding each additional polyp (0, 1, 2+), likelihood of finding each additional adenoma (0,
1, 2+), likelihood of finding a right-sided polyp (no polyp, left only, at least one rightsided polyp found), and likelihood of finding a smaller polyp (no polyp, at least one
small(≦5mm) polyp found, at least one medium (6-9mm) found, at least one
large(10+mm) polyp found). The key independent variable of interest is sedation type
(propofol or MM) and the control variables are bowel preparation status, patient age, race,
gender, was this a PCP training procedure, and the number of polyps found.
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Because patients are nested within physician and are likely to experience a unique
physician level effect, we conducted multilevel modeling. Patients within a physician
panel are considered to have an exchangeable correlation, and any two patients served by
different physicians are considered uncorrelated. Generalized estimating equation (GEE)
is used to test the associations of interest. To model dichotomous dependent variables,
such as the likelihood of detecting a polyp/adenoma/advanced adenoma in subjects,
logistic GEE regression model was used. For ordinal variables, such as the likelihood of
finding each additional polyp/adenoma, the likelihood of finding at least one right colon
polyp, likelihood of finding increasingly smaller polyps, and the likelihood of having a
shorter procedure duration an ordered logistic GEE regression model was used. The score
test in SAS applied to verify the validity of this assumption. Our study hypothesizes that
propofol sedation is more likely to be associated with finding a polyp/adenoma relative to
no polyp/adenoma, and the same odds applies to finding an additional polyp/adenoma
Bowel preparation status significantly affects procedure completion and therefore lesion
detection rates. Radaelli showed 40% lower odds of procedure completion with good
bowel preparation vs. excellent (Radaelli 2008). Therefore in assessing the effectiveness
of sedation type it is essential to adjust for bowel preparation status.
Results
Of total 20,540 study eligible patients (provided screening colonoscopies from
September 4, 2001 through February 4, 2011), all pre-April 1 2006 patients were sedated
with MM, 11,266 (54.85%), and from April 1, 2006 with propofol, 9,274 patients
(45.15%). Table 4-5 shows the sample distribution by demographic and procedure
characteristics. The majority were aged 50 – 59 years (44.5%), female (53.82%), and
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Black (51.72%). Polyps were detected in 61.6% of patients, and majority of patients had
only small polyps (91.8% ≤5mm). Among those with polyps, half of the patients had at
least one right colon polyp (49%).
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Table 4-5: Demographic and procedure characteristics of the study sample
No. of patients
n (%)
Sedation type
M-M
11,266 (54.85)
Propofol
9,274 (45.15)
Good bowel preparation†
Yes
18,613 (90.62)
No
1,561 (7.60)
Patient age
<50 years
3,792(18.46)
50-59 years
9,138(44.49)
60-69 years
5,066(24.66)
70-89 years
2,544(12.39)
Patient gender*
Male
9,390(45.72)
Female
11,054(53.82)
Patient Race*
Whites
9,139(44.49)
Blacks
10,623(51.72)
Other
682(3.32)
Number of polyp found**
0
7,772 (37.84)
1
6,383 (31.08)
2+
6,268 (30.52)
Polyp size†
No polyps
7,772 (37.84)
11,727 (57.09)
Small (≦5mm)
Medium (6-9mm)
591 (2.88)
Large (10+mm)
377 (1.84)
Polyp anatomic location††
No polyps
7,772 (37.84)
Left colon
6,387 (31.10)
Right colon
6,273 (30.54)
* Total of 96 patients missing information on gender and race.
**Total of 117 patients with missing information on number of polyps.
† 366 patients missed sedation type in combination with bowel preparation information.
†† 73 patients had missing polyp size information, 108 patients were missing information on
polyp anatomic location.
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Table 4-6 presents the colonoscopy performance quality and lesion outcomes
distributed by sedation type. The polyp detection rate was higher in propofol-sedated
patients (63.49%) compared to MM (61.07%) (p<.05), as was the mean number of polyps
found per patient (1.33 vs. 1.06) (p<.0001). The patterns of differences in adenoma
detection and advanced neoplasm detection also follow the above pattern (propofol:
31.73%, MM: 30.86% for adenomas and 7.12% vs. 6.46% for advanced neoplasms, all
p<.05), as also the mean number of adenomas found per patient screened (0.53 vs. 0.48),
the detection rate for small polyps (58.01% vs. 56.34%), and for any right colon polyp
(31.3% vs.29.9%). The mean procedure time is shorter with propofol sedation (25.08 vs.
26.25 min for MM), both when polyps were detected (27.51 vs. 28.33 min.) and no
polyps detected (20.69 vs. 22.66 min.).
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Table 4-6: Indicators of colonoscopy quality by sedation type
Midazolammeperdine
mean / n(%)
No. of patients
11,266(54.85)
Cecum intubation rate (% of cases)
10,719 (95.14)
Good bowel preparation
Yes
10,112 (89.76)
No
847 (7.52)
Lesion detection rates
Polyp detection rate (% of cases)*
61.07
Number of polyps detected per
1.06±1.19
subject(mean, SD)**
Adenoma detection rate (% of cases)**
30.86
Number of adenomas detected per
0.48±0.88
subject(mean, SD)**
Advanced neoplasms (% of cases)**
6.46
Procedure duration
All colonoscopies
Total procedure time (min)**
26.25±17.52
Colonoscopies with no polyp found
Total procedure time (min)**
22.66±11.62
Colonoscopies with polyp(s) found
Total procedure time (min)**
28.33±19.86
Polyp size**†
No polyps
4,386 (38.93)
6,347 (56.34)
Small polyp with or without medium or large
polyp(≦5mm)
Medium with/without large polyp (6-9mm), no
306 (2.72)
small polyp
Large polyp only (≥ 10mm)
189 (1.68)
Polyp anatomic location**†
No polyps
4,386 (38.93)
Left colon only
3,402 (30.20)
Right colon (with or without left colon polyp)
3,370 (29.91)

Propofol

p-value

mean / n(%)
9,274(45.15)
9,098 (98.10) P<.0001
P<.0001
8,501 (91.66)
714 (7.70)
63.49
P=.0004
1.33±1.52 P<.0001
31.73
P=.001
0.53±1.00 P<.0001
7.12

P=.0004

25.08±11.48 P<.0001
20.69±9.33 P<.0001
27.51±11.84 P<.0001
P=.003
3,386 (36.51)
5,380 (58.01)
285 (3.07)
188 (2.03)
P<.0001
3,386 (36.51)
2,985 (32.19)
2,903 (31.30)

† 73 patients had missing polyp size information, 108 patients were missing information on polyp
anatomic location.

Table 4-7 and 4-8 show the associations between sedation type and colonoscopy
quality indicators adjusting for patient demographics and other procedure-related factors.
The adjusted procedure time is showed somewhat longer duration with MM sedation than
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propofol sedation although it did not attain statistical significance (0.97 min longer,
p=.093). Propofol sedation was associated with slightly higher odds of finding advanced
neoplasm(s) (adjusted OR: 1.14, 95%CI: 1.01, 1.29) and slightly higher odds of finding
an additional polyp (adjusted OR: 1.25, 95%CI: 1.07, 1.46) compared to MM sedation.
The associations were not statistically significant for the likelihood of finding at least one
polyp and finding an adenoma (adjusted ORs: 1.11 and 1.08, respectively). Similarly the
likelihood of finding at least one right-sided polyp(s) was not significant (adjusted OR:
1.10), as was the likelihood of finding increasingly smaller polyp(s) (adjusted OR: 1.08)
because all confidence intervals spanned 1.0.
Unlike the sedation type, bowel preparation status is showing consistently high
and statistically significant associations. Good bowel preparation is significantly
associated with a shorter procedure durations (3.46 min, p<.0001). Better bowel
preparation was also associated with higher likelihood of finding polyp(s) (1.43,
p<.0001), finding adenoma(s) (1.18, p=.005), finding an additional polyp (1.38,
p<.0001), finding at least one right-sided polyp (1.31, p<.0001) and finding increasingly
smaller polyp(s) (1.42, p<.0001). The likelihood of finding advanced neoplasm(s) was
not associated with bowel preparation status with the exception of finding an additional
adenoma when the bowel preparation status was good vs. poor (adjusted OR: 1.16,
95%CI: 1.03, 1.30).
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Table 4-7: Adjusted estimates of colonoscopy performance and outcome quality
indicators by sedation type*
Dependent variables (colonoscopy quality indicators)
Procedure
Likelihood of
Likelihood of Likelihood of finding
time (min) finding polyp(s)
finding
advanced
neoplasm(s)
(logistic GEE)†
adenoma(s)
(logistic GEE )†
(logistic GEE )†
β p-value OR
95%CI
OR
95%CI
OR
95%CI
Sedation type
M-M
0
0
1.00
1.00
1.00
1.00
1.00
1.00
Propofol
-0.97 P=.093 1.11 0.97,1.26 1.08 0.98,1.19 1.14
1.01,1.29
Good bowel preparation
Yes
-3.46 P<.0001 1.43 1.29,1.60 1.18 1.05,1.33 1.10
0.89,1.35
No
0
0
1.00
1.00
1.00
1.00
1.00
1.00
Patient age
<50 years
0
0
1.00
1.00
1.00
1.00
1.00
1.00
50-59 years 0.52 P=.166 1.33 1.21,1.47 1.51 1.35,1.68 1.31
1.08,1.60
60-69 years 2.06 P<.0001 1.61 1.48,1.75 2.17 1.97,2.38 1.81
1.54,2.13
70-89 years 2.93 P<.0001 1.83 1.60,2.09 3.02 2.69,3.38 2.17
1.75,2.70
Patient gender**
Male
0
0
1.00
1.00
1.00
1.00
1.00
1.00
Female
1.11 P<.0001 0.75 0.70,0.80 0.64 0.60,0.68 0.65
0.57,0.74
Patient race**
Whites
0
0
1.00
1.00
1.00
1.00
1.00
1.00
Blacks
-0.86 P=.082 0.90 0.80,1.01 0.88 0.81,0.97 1.03
0.90,1.17
Other
0.65 P=.2017 0.89 0.73,1.10 0.84 0.69,1.01 0.79
0.55,1.15
th
Was this a PCP training procedure? (≤140 procedure for the PCP)
Yes
0
0
1.00
1.00
1.00
1.00
1.00
1.00
No
-3.93 P<.0001 0.92 0.80,1.05 0.90 0.81,0.99 0.88
0.75,1.02
Number of 3.16 P<.0001 polyp found
* Model controlled for protocol type and whether bowel preparation is “Good” or “No Good”.
** Total of 96 patients was missing information on gender and race and excluded from analysis.
† Categories modeled are “No” and “Yes”.
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Table 4-8: Adjusted estimates of colonoscopy performance and outcome quality
indicators by sedation type*
Dependent variables (colonoscopy quality indicators)
Likelihood of
Likelihood of
Likelihood of
Likelihood of
finding an
finding an
finding at least finding increasingly
additional polyp†
additional
right colon polyp(s) smaller polyp(s)
(ordered logistic
adenoma†
(ordered logistic
GEE)††
GEE)†††
OR
95%CI
OR
95%CI
OR
95%CI
OR
95%CI
Sedation type
M-M
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
Propofol 1.25 1.07,1.46 1.09 0.99,1.20 1.10 0.96,1.26 1.08 0.95,1.23
Good bowel preparation
Yes
1.38 1.24,1.52 1.16 1.03,1.30 1.31 1.19,1.45 1.42 1.29,1.57
No
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
Patient age
<50
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
years
50-59
years
1.33 1.22,1.45 1.52 1.37,1.69 1.38 1.26,1.51 1.31 1.20,1.44
60-69
years
1.68 1.55,1.81 2.26 2.06,2.48 1.79 1.67,1.92 1.55 1.43,1.68
70-89
years
1.87 1.66,2.10 3.15 2.82,3.51 2.20 1.97,2.46 1.72 1.51,1.95
Patient gender**
Male
0
0
0
0
1.00
1.00
1.00
1.00
Female 0.73 0.68,0.78 0.62 0.59,0.66 0.72 0.68,0.77 0.78 0.72,0.83
Patient race**
Whites
0
0
0
0
1.00
1.00
1.00
1.00
Blacks 0.87 0.78,0.97 0.89 0.81,0.97 0.92 0.83,1.02 0.89 0.79,1.00
Other
0.85 0.70,1.02 0.84 0.69,1.02 0.85 0.71,1.02 0.93 0.76,1.13
Was this a PCP training procedure? (≤140th procedure for the PCP)
Yes
0
0
0
0
1.00
1.00
1.00
1.00
No
0.92 0.80,1.06 0.89 0.81,0.99 0.93 0.81,1.05 0.93 0.81,1.07
* Model controlled for protocol type and whether bowel preparation is “Good” or “No Good”.
** Total of 96 patients was missing information on gender and race and excluded from analysis.
† Categories modeled are 0, 1, 2+.
†† Categories modeled are “No polyp”, “Left only”, “at least one Right polyp”.
††† Categories modeled are “No polyp”, “Small”, “Medium”, “Large”.
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Discussion
Propofol sedation has been of interest to gastroenterologists because it enables
very rapid induction of deep sedation and rapid recovery. This enables more efficient
utilization of the endoscopist’s time as well as the additional costs of the associated staff
and infrastructure while supporting patients’ gradual recovery with MM and other
sedation types. Additional advantages of propofol that are well-documented are far better
and reliable pain control and higher patient satisfaction.
A key question however is whether it improves the quality of the procedure in
terms of achieving pan-colonic polyp clearance, because the additional costs incurred for
propofol administration may be justifiable to payers if the ultimate clinical outcomes and
downstream cost reductions to be achieved can be demonstrated. This is the first study to
evaluate this question using a very large series in an unusual setting where rigorous
quality assurance mechanisms and documentation are in place, elements of the clinical
protocol other than sedation type were kept constant across providers (or documented for
providers not adhering to certain colonoscopy protocol elements), and a large number of
providers’ procedures are included in the sample (59 providers).
We find that while there is a suggestion of a positive association of propofol
sedation with improved lesion detection and clearance as measured by sensitive
indicators, the results did not attain statistical significance except in respect of one
indicator, the advanced adenoma detection rate, and in a reduction in procedure time. We
used several uncommon indicators of colonoscopy quality in addition to the standard
measures reported routinely such as adenoma detection rates, mean number of adenomas
per screened patient. These include the likelihood of detecting a small adenoma detection,
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and of detecting the relatively elusive right colon polyp. Although we found a consistent
pattern of slightly better detection of lesions with propofol sedation compared to MM
sedation, the results did not attain statistical significance despite our large sample size.
Our findings are similar to those of other studies that examined the depth of sedation
rather than sedation agents used (Paspatis 2011). Our findings may be due to the
possibility that the study center ensures deep sedation for all patients regardless of
sedation type.
An important study finding is the role of bowel preparation status in the detection
rates of all types of lesions, particularly the more elusive lesions such as smaller
adenomas and right colon polyps which could be perilous to the patient if left behind. Our
study validates the findings of Radaelli et al and adds to the literature by extending the
documented associations to the finer indicators of quality, small adenoma detection,
likelihood of detecting each additional adenoma, and likelihood of detecting a right colon
polyp. Missing of right colon polyps at colonoscopy is documented to be widespread and
thought to be a major driver of a large proportion of colorectal cancers arising despite
colonoscopy screening.
In summary, our findings suggest that propofol sedation may contribute
marginally to improved colonoscopy quality, although quality improvement efforts may
be better rewarded if focused on measures to improve patient bowel preparation through
efforts directed at patients for example, through patient navigation. Regarding propofol
sedation itself, our findings suggest that endoscopists’ decisions to adopt propofol
sedation should be guided more by considerations of patient comfort and satisfaction, as
well as efficiency of endoscopist time utilization rather than an expectation of improved
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lesion detection rates. Our study does not provide support for adoption of propofol
sedation for the purpose of improving the colorectal cancer prevention effectiveness of
colonoscopy screening.
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Appendix A DATA MANAGEMENT PROCESS

•

Preparing and cleaning the data:
De-identified data on all colonoscopies conducted during September 4, 2001 and

February 4, 2011 were downloaded from the SCMEC’s administrative and clinical
datasets for this study. To prepare and clean the data ready for analysis, the data
collection and management processes are as below:
V:\ColScope\SCMEC\Data\SASfilz\old stuff\ImportData\ImportData.sas
Several datasets imported from SCMEC on October 10, 2007 including physician
dataset, appointment dataset, billing dataset, and polyp dataset imported to USC system.
(Import Data. sas)
V:\ColScope\SCMEC\Data\SASfilz\old stuff\CombineData\2011\CombineData\PCP
Data.sas
Physician demographics data was imported from the SCMEC in 2007 including
ID, name, gender, race, age as of 2007, year of graduation, area of specialty, years of
experience since graduation as of 2007, is this physician board certified and the reason
for exclusion if this physician is not qualified to our study. Total of 64 physicians were
read in (Rawdat.pcp) and extra 3 physicians (extrapcp) were updated later adding up to
67 physicians in our original physician dataset (Rawdat.pcp2).
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V:\ColScope\SCMEC\Data\SASfilz\DA2012\Polyp Data 10-17-12.sas
oldraw.polypupdate2 (n=180)
This is an update patch done in 2008. This file has polypid and the polyp_results
coded as 1-9 (this was obviously from patient charts). This file contained polyp data
2001-2002, was originally found no pathology text, but discovered path_results in
colonoscopy sheet of “Coldata.xls”. “Compress” function was used to return a character
string with specified characters removed from the original string for operationid and
polypid.
Old polyp data was read in from polyps sheet of Coldata.xls covering polyp
information from 9/1/1999 to 11/1/2007. Remove duplicates due to data download
(n=16,426) and data entry (n=1). Old polyp data (N=16,427) was merged with the 2008
update (N=180) after it was cleaned, named as “OldPolyps1 (N=16,607).
New polyp dataset of 32,726 observations was then read in, this polyp dataset
covered from 2001 to 2011 (V:\ColScope\SCMEC\Data\Rawdata\2011\polyps 2011.xlsx).
“ignoredestroyed” and “dysplasia” were reformatted from characters to numeric variables.
After cleaning up some default setting of the dataset, old polyp data that were missing
data with info was updated from the new polyp data.
AllPolyps: Update old polyps (n=16,607) with new polyps (n=32,726). Because
oldraw.polypupdate2 (n=180) is not contained in newpolyps, the combined AllPolyps has
32,908.
Several correction and updating codings were applied afterwards as bellows:
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1. “Substr” function for taking substrings of matrix elements for “OperationId” to
“OperId”,
2. Data value recode – erroneous value due to limitation when importing and
missing value format recode,
3. Variable rename,
4. Dysplasia update coding from pathologytext and path_results matching both by
OperId/polypno and polypId.
Apply correction code for missing data and recodes to all polyps (%include
'V:\ColScope\SCMEC\Data\SASfilz\DA2012\CorrectionUpdateCoding\MissingDataUpd
ates10-10-12.sas';)
The updates of Summer 2011 for missing value were read in from Access
worksheet, the datasets were: (Access datasets are at
"V:\ColScope\SCMEC\Data\Rawdata\2011\NewMissingData\SCMEC Missing Data
updated 09292011\SCMEC Missing Data 1.accdb" and
DATABASE="V:\ColScope\SCMEC\Data\Rawdata\2011\NewMissingData\SCMEC
Missing Data updated 09292011\SCMEC Missing Data 2.accdb";)
1. PolRes for polyp_result update,
2. PolSize for Polypsize update, after reading in we manually recoded various
formats couldn’t be specified due to data entry,
3. PolQuant for PolypQuantity update,
4. PolLoc for Polyplocation update,
5. PolCol for Color update, the “color” variable was renamed to “morphology”
variable, and a “macro” function for morphology was used to create
156

“PeduncSessile”, “Erythematous”, Flat”, “ Multilobular”, “Violaceous”, and
“ Serrated” variables. For “ Serrated” variable, text search was additional used on
pathologytext to fully capture the endoscopist procedure notes,
6. PolHow for polypectomy update.
“V:\ColScope\SCMEC\Data\SASfilz\DA2012\CorrectionUpdateCoding\PolypRe
sultsUpdate10-16-12.sas”, this program used pathologytext (hierarchical text search) and
pathresults (linked by combination of OperID and polypno) and manual review as total of
4,746 to update to polyp_result.
Now, we have pathresults, pathologytext and polyp_result variables all for coding
the results of the polyp, therefore, we incorporated and updated them into “polyp_result”
variable using the Correction and Update Coding.
Remove polyps from Minhas Hospital procedures
After the updating program was applied, we removed Minhas-procedure polyps
by getting the operationid of the procedures from Rawdat.MinhasHospital dataset.
(polyps from 34 procedures were removed) (See line 449-461)
How we produced final product of “Rawdat.finalpolyps2012” of this program
It was created after categorizing Adenoma, AdvAdenoma SerratedAdenoma,
HyperPolyp, NormoPolyp, Carcinoid, Carcinoma, and AdvNeoplasm variables using
polyp_result and dysplasia level.
V:\ColScope\SCMEC\Data\SASfilz\old
stuff\CombineData\2011\CombineData\Colonoscopy Data.sas
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Rawdat.colonoscopy was imported from “coldata.xls” as colonoscopy procedure
data from the SCMEC (Rawdat.colonoscopy has 17,790 procedures, 30 duplicated entries
by SCMEC staff were deleted. Total now is 17,760.)
The revised colonoscopy dataset is now updated with n=17,773 from
rawdat.colonupdate (this should be chart review, missing data capture on procedure times
etc.) The output as “colonoscopy01” has 17,761 observations.
This was now updated with missing operation time, intubation and prep status
data for 227 observations (rawdat.colonupdate2(n=227) ) from
V:\ColScope\SCMEC\Data\Rawdata\Update7-21-08\ ColonoscopyUpdateN227.xls. This
update output as “colnoscopytemp” has 17,761 observations.
Update new procedures May 2008 to Dec 2011 are now updated using
V:\ColScope\SCMEC\Data\Rawdata\2011\Colonoscopy2011.xlsx (n=9848).
[colonoscopytemp(17,761) + colonoscopyNew3 (n=9,848) should be = 27,609, obviously
some duplicates in new dataset, therefore colonoscopy has 27,472.]
All of the updates were updated to Rawdat.colonoscopy,
"V:\ColScope\SCMEC\Data\SASfilz\old stuff\Correction coding\CorrectTimes.sas" and
"V:\ColScope\SCMEC\Data\SASfilz\old stuff\Correction coding\CorrectAge.sas" were
both brought in for procedure times and age corrections. Procedures prior September
2001 were output to pre9_2001 (n=808), procedures with missing patientID were output
to noptid(n=10), and the remaining eligible were output as colnoscopy1temp(n=26,654),
which is post September 2001 procedure dataset.
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In Summer of 2011 over 10,000 patient charts review for data collection on
missed/discrepant patient/procedure information including check on patient date of birth,
date of procedure, bowel preparation, incomplete reason, procedure time point (time of
insertion, viewing cecum and withdrawal),and pathology report to verify polyp
information including polyp size, location, how taken, and polyp result. Updates were
stored as Access format as “newmissing1”(n=2,024) and “newmissing2”(n=2,023) from
“V:\ColScope\SCMEC\Data\Rawdata\2011\NewMissingData\SCMEC Missing Data
updated 09292011\SCMEC Missing Data 1.accdb” and
“V:\ColScope\SCMEC\Data\Rawdata\2011\NewMissingData\SCMEC Missing Data
updated 09292011\SCMEC Missing Data 2.accdb” when two teams were working on-site
collecting data. After combining and the management of the dataset (e.g., we could not
find the patientid for the patient chart, and it turns out there were two patientids for one
patient and we got the old one, the SCMEC helped us to figure out the corresponding
new patientid for the patient so that we can locate the patient chart for review, therefore
patientid update was done here and calculated the procedure time as minute per the
documented timing of start and end of the colonoscopy and timing of viewing cecum,
patient age calculated using interval function (int) between procedure date and patient
date of birth), two missing update datasets were output as “allrecentnewupdate”(n=4,047)
and update into colonoscopy1temp (post September 2001 procedure dataset).
In colonoscopy2, "V:\ColScope\SCMEC\Data\SASfilz\old stuff\Correction
coding\CorrectTimes.sas", "V:\ColScope\SCMEC\Data\SASfilz\old stuff\Correction
coding\CorrectAge.sas", "V:\ColScope\SCMEC\Data\SASfilz\old stuff\Correction
coding\IncompleteReasons.sas", and "V:\ColScope\SCMEC\Data\SASfilz\old
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stuff\Correction coding\PolypMissing.sas" were brought in for procedure times, age,
incomplete reasons, and polypmiss (polyp data not found in records-exclude from
denominator) corrections.
Text search on “ProcComments” was used here for excluding cancelled
procedures (n=39) and on “comments” PLUS providerID in (19,36,37,57) for excluding
Minhas trained procedures (n=34).
After excluding, procedures in Colonoscopy2(n=26,523), cancandnull(cancelled
procedures and null, appointment taken not show up, n=55), ColPrepNull(n=2),
howmany(patientid available chart not traceable, n=1), rawdat.MinhasHospital(n=34) and
39 cancelled appointments.
Physician specialty was recoded based on
“V:\ColScope\SCMEC\Data\Rawdata\PCP\PhysicianList go through with Dr Lloyd 503-2012.xlsx”, this file was new update since 2008 that we went through with Dr Lloyd
of each physician to determine the specialty and the training process and does the
physician should be included or excluded from our study.
Based on the “PhysicianList go through with Dr Lloyd 5-03-2012.xlsx”,
physician specialty was categorized here of providerID in (1,64,22,56,59) as specialist,
PCPCs for the remaining physicians.
The physician specialty now is correctly classified under “specialist” variable.
The “ColPCPSeq” variable was created using macro function and patched in
“colonoscopy2” procedures data and output as “colonoscopy3”. The provider
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demographics were read in from “rawdat.pcp2” and patched in “colonoscopy3”, output as
“Colonoscopy4”.
V:\ColScope\SCMEC\Data\Rawdata\2011\MissingRaceAndGender 8-19-2011.xlsx
During August of 2011, a round of data collection on filling in 2645 missing
patient gender and race after exporting data from the SCMEC (MISYS) was carried (refer
to MissRaceSex sheet). After this round of collecting on patient gender and race, the data
was checked on duplicity and 2390 patients were found to have conflicts on duplicated
entries from MISYS (DuplicateRace&Sex MYSIS sheet).
The RaceandGender updates in 10-18-2012 was fold in the updates in Spring
2012 “rawdat.racegenderregdata4_30_2012” by include function of
'V:\ColScope\SCMEC\Data\SASfilz\DA2012\CorrectionCodeForTheRegistry\PatAgeGe
nderRaceCorrectionCode SCMEC 10-17-2012.sas'(n=2722) and
'V:\ColScope\SCMEC\Data\SASfilz\DA2012\CorrectionCodeForTheRegistry\PatGender
RaceCorrectionCode.sas'(n=2714), output as “RaceAndGender”. “RaceAndGender” was
later merged in “Colonoscopy4” and output as final permanent product of “Colonoscopy
Data.sas” as “rawdat.FinalColonoscopy2012”.
V:\ColScope\SCMEC\Data\SASfilz\DA2012\ Combine polyp and procedure datasets 1017-2012.sas
Final product of Polyp Data 10-17-12.sas of “rawdat.finalpolyps2012” and
Colonoscopy Data.sas of “rawdat.FinalColonoscopy2012” were read in.
1. Summarize polyps as “SumPolyps” and polyp type as “SumPolypTypes” by
procedure.
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2. ReferalReason and HistColSurgDis updates were fold in
“rawdat.FinalColonoscopy2012” by include function of
‘V:\ColScope\SCMEC\Data\SASfilz\DA2012\CorrectionCodeForTheRegistry\Re
feralReason_HistColSurgDisCorrectionCode07252012.sas'.
3. Identify subjects with multiple procedures using frequency function in
“rawdat.finalcolonoscopy2012” to count the number of procedure for each
patientid and output as “MultiCol”. Merged “MultiCol” back into
“rawdat.finalcolonoscopy2012” by patientid to identify the “FirstProcedure” and
“RepeatCol” variables using first.id function and count product, output as
“Procedures2”.
4. “SumPolyps” and “SumPolypTypes” were merged with “Procedures2” by
operationid.
5. The “referralreasongrp” variable was in a separate dataset called “RawDat.Ref
(n=456)” and was not read in to “analytic.UpdatedRevProcFinalOct192012”, so
bring them in here, then manually applied 10 corrections made from “Surgical
referrals 10262011+ History Colon.xlsx”.
6. Output as “analytic.UpdatedRevPolypFinalOct192012” and
“analytic.UpdatedRevProcFinalOct192012” as final products of polyp and
procedure datasets for analysis in this study.

E. Defining the key variables of interest
The question to be answered in this research is the screening colonoscopy quality.
Adenoma detection is our key dependent variable to define the quality. To define the
162

adenoma, endoscopists first find the polyps during the colonoscopy, classify the polyp by
its appearance, and take part of the lesion to lab for biopsy to confirm the histology of the
polyp. Therefore, we first look at polyp detection and go to adenoma detection as our
main interest variable.
Polyp detection rate is defined as the percentage of patients with at least one
polyp was found. Each polyp has a polypid and a procedureid to link to the patient it
belongs to. To identify the patient with polyp or not, we summarize the polyp by
patientid in polyp dataset. If the patientid exist in the polyp summary dataset, the patient
was coded as “Yes” in polyps column in procedure dataset, and vice versa. To calculate
polyp detection rate, patients with polyps equal to “Yes” are divided by total patients.
Adenoma detection rate follows the same logic when creating.
data SCMECProcPolyp1 (drop=polres rename=(pcp=ProviderID)) polyponly;
merge Procedures2 ( in=inprocs )
SumPolypTypes (in=inPolpyps)
SumPolyps (rename=(count=SumPolyps) drop=percent);
by operationid;
ProcedureId=operationid;
** create polyps yn **;
if inprocs and inPolpyps then polyps=1; else polyps=0; format polyps yn.;
** add missing to polyp level histology **;
if polyps eq 0 then
Do;
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SumPolyps=0; SumAdenoma=0; SumAdvAdenoma=0; SumSerratedAd=0;
SumHyperPolyp=0; SumNormoPolyp=0; SumCarcinoid=0; SumCarcinoma=0;
SumAdvNeoplasm=0;
End;
else if polres eq . then
Do;
SumPolyps=.m; SumAdenoma=.m; SumAdvAdenoma=.m; SumSerratedAd=.m;
SumHyperPolyp=.m; SumNormoPolyp=.m; SumCarcinoid=.m; SumCarcinoma=.m;
SumAdvNeoplasm=.m;
End;
For the number of polyps found per subject, the polyp was summarized by
patientid in polyp dataset and the exact number of count was merged into procedure
dataset as SumPolyps by patientid, as well as the number of adenomas found per subject,
named SumAdenomas.
proc freq data=SCMECpolyps noprint;
tables operationid/out=SumPolyps;
run;
proc sort data=SCMECpolyps; by operationid;
proc summary data=SCMECpolyps noprint;
var CountPolyp Adenoma AdvAdenoma SerratedAdenoma HyperPolyp NormoPolyp
Carcinoid Carcinoma AdvNeoplasm PolypQuantity Polyp_result;
output out=SumPolypTypes (drop=_type_ _freq_)
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sum = SumPolyps SumAdenoma SumAdvAdenoma SumSerratedAd SumHyperPolyp
SumNormoPolyp SumCarcinoid SumCarcinoma SumAdvNeoplasm SumPolypQuantity
PolRes;
by operationid;
run;
The protocol type is classified based on providerID from SCMEC, providerID
equal to 56 and 64 were classified as 1-person technique specialists, whereas providerID
equal to 1, 22 and 59 were classified as 2-person technique specialists, and remaining
procedures are all 2-person technique PCPs.
if ProviderID in (56,64) then protocol=1;*56=Kudchadkar, 64=Sweeney (n=604);
else if ProviderID in (1,22,59) then protocol=2;*1=Lloyd, 22=Minhas, 59=Yunis
(n=4742);
else protocol=3;* PCP (n=15224);
format protocol protocol.;
proc format library=library;
value protocol 1 = '1-person Specialist'
2 = '2-person Specialist'
3 = '2-person PCP';
run;
The sedation type is categorized by procedure date, every procedure conducted
prior April 1, 2006 was categorized as Midazolam-meperdine sedated procedure, while
the counter part of the procedure dataset was coded as propofol sedated procedure.
if . lt procdate LT mdy(4,1,2006) then Anesthesia=0;
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else Anesthesia=1;
format Anesthesia Anesthesia.;
proc format library=library;
value Anesthesia 0='Dermol'
1='Propofol';
run;
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